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ABSTRACT 
Uncoupling protein 2 (UCP2) is one of five UCP homologues found in the inner 
mitochondrial membrane that transports protons from the intermembrane space to the 
mitochondrial matrix. In turn, the proton motive force is dissipated and less ATP is produced in 
the mitochondria. UCP2 is proposed to influence insulin secretion in type II diabetes, and 
decrease the amount of reactive oxygen species produced in the mitochondria, however the 
detailed mechanism of ion (proton and anions) transport in UCP2 and other UCP homologues are 
not fully understood. Sequence alignment analysis performed on proteins in the mitochondrial 
carrier family (MCF) including UCPs, identified a matrix network of positively and negatively 
charged residues that were proposed to form salt bridges and mediate substrate translocation 
through the proteins. In this study, the positively charged lysine residues in the matrix network 
were investigated for their influence on the proton transport and nucleotide binding activity of 
UCP2. For this reason, four UCP2 mutants: K38Q, K141Q, K239Q, and K38Q/K239Q (double 
mutant) and native proteins were expressed in bacterial membranes. After which the 
conformation of the purified proteins was analyzed with far-UV circular dichroism (CD). 
Finally, a fluorescence-based assay was used to study the proton transport and nucleotide binding 
properties of the proteins. The overall conformations of the proteins were α-helical but the shifts 
in negative ellipticity at 208 nm and 222 nm observed for the mutants inferred a change in the 
helical packing of these proteins compared to the wild type. In addition, the mutant proteins had 
proton transport rates that were 35% (K38Q and K239Q) and 65% (K141Q and double mutant) 
less than the native UCP2. In the presence of ATP, the proton transport rates of the mutant 
proteins decreased by 3-6% except for K38Q that had a 38% decrease in proton transport 
activity. In summary, these results revealed that the positively charged lysine residues in the 
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matrix network could participate in a salt bridge interaction that regulates the degree of helical 
packing, the ion transport activity and nucleotide binding properties in UCP2. 
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CHAPTER 1: INTRODUCTION 
1.1. Mitochondria and ATP Production 
 Mitochondria are membrane-bound organelles located in the cytoplasm of eukaryotic 
cells. In the mitochondria, energy derived from the oxidation of carbohydrates and fatty acids are 
converted into the cells energy currency known as adenosine triphosphate (ATP) [1]. ATP is 
used to drive many cellular functions, including, but not limited to, muscle contraction, cell 
division, signalling, protein folding, and protein degradation [1, 2].   
The mitochondrion structure is composed of an outer mitochondrial membrane (OMM), 
an intermembrane space (IMS), an inner mitochondrial membrane (IMM) and a mitochondrial 
matrix (MM) (Figure 1 and 2) [2, 3]. The OMM separates the IMS from the cytosol and it’s 
composed of 50% phospholipids and 50% proteins by weight. The OMM includes prions, which 
makes it permeable to small molecules like coenzyme Q and ATP [4]. Additionally, the IMM 
separates the IMS from the mitochondrial matrix and is less permeable to solutes and ions 
compared to the OMM. The IMM has a 25% phospholipid and 75% protein weight  
composition [4]. In comparison, the IMM has a higher cardiolipin (CL) content (20% of total 
lipid) than the OMM. The IMMs high CL content could lead to specific CL-protein interactions 
that may modulate the activity of certain proteins in the IMM including complexes in the 
electron transport chain [5], ATP/ADP carrier (AAC) [6], and uncoupling proteins (UCPs) [7]. 
The IMM is folded to form invaginations called cristae (Figure 1) [4]. These invaginations are 
proposed to increase the membrane surface area and ensure ATP synthase and protein complexes 
of the ETC are organized in the IMM to maximize ATP production [4]. Furthermore, cristae with 
large surface areas are abundant in the mitochondria of tissues with high respiration rates, such 
as muscle and neurons [4].   
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 ATP is produced in the mitochondria through the process of oxidative phosphorylation. 
More specifically, the oxidation of energy-rich compounds such as carbohydrates and fatty acids 
(FAs) results in the reduction of NAD
+
 and FAD into NADH and FADH2 [4]. These reduced 
electron carriers supply their electrons to protein complexes in the electron transport chain 
(ETC). The ETC is composed of: NADH dehydrogenase (complex I), succinate dehydrogenase 
(complex II), cytochrome c reductase (complex III), and cytochrome oxidase (complex IV) [8]. 
The movement of electrons through these complexes ETC results in the reduction of oxygen to 
water and pumping of protons (by complexes I, III, and IV) from the matrix into the 
intermembrane space [8]. This proton pumping enhanced an electrochemical gradient (proton 
motive force (PMF)) across the IMM that is the driving force for transporting the protons back 
into the matrix through the F0F1 ATP synthase. The dissipation of the PMF through ATP 
synthase provides the energy for this complex protein to synthesize ATP from adenosine 
diphosphate (ADP) and inorganic phosphate (Pi) (Figure 2) [8]. 
 The PMF generated by the ETC is also dissipated by other proteins in the IMM, resulting 
in uncoupling the ETC from ATP synthesis. The uncoupling effect accounts for 25% basal 
metabolic rate and can be mediated through several proteins such as the phosphate transporter, 
glutamate carrier, AAC, and uncoupling proteins (UCPs) [4, 8]. In brown adipose tissues (BAT) 
the dissipation of the PMF by UCP1-mediated proton leakage, decreases the ratio of 
[ATP]/[ADP] and the metabolic transformation of substrates required for the electron transport is 
released as heat [9]. The heat generated in BAT results in non-shivering thermogenesis in 
neonatal and cold-acclimatized mammals [9].  
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Figure 1: An Electronmicrograph of the mitochondrion. The long arrows indicate the outer 
mitochondrial membrane, intermembrane space, inner mitochondrial membrane, and the 
mitochondrial membrane. The mitochondrion was isolated from chick cerebellum. Reprinted by 
permission from Elseivier (Frey, T., Renken, C., and Perkins, G. (2002). Insight into 
mitochondrial structure and function from electron tomography. Biochimica et Biophysica Acta 
(BBA) - Bioenergetics, 1555(1), 196–203), copyright 2002. 
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Figure 2: Process of ATP synthesis and UCP-mediated proton leakage in the mitochondria. 
NADH and FADH2 transfer their electrons to the protein complexes in the electron transport 
chain. As the electrons move through the complexes, protons are pumped from the matrix into 
the intermembrane space which forms a proton motive force across the inner mitochondrial 
membrane. The proton motive force drives ATP production in ATP synthase, however, its 
dissipation by UCP decreases ATP synthesis. Stephanie Uwumarenogie created this image with 
the Microsoft paint.  
 
1.2. Uncoupling Proteins  
Research in the late 1970’s established BAT as the major source of non-shivering 
thermogenesis in hibernating and infant mammals [10, 11].  Experimental evidence showed that 
a key contributor to heat production in BAT was the uncoupling of cellular respiration from ATP 
synthesis in the mitochondria [12]. However, it wasn’t until 1978 that photo-affinity labelling 
experiments showed that rat isolated mitochondria had increased proton leakage in the presence 
of free FAs [13]. In turn, decreased proton leakage was observed in the presence of purine di- 
and tri-phosphate nucleotides [13]. It was then discovered that an IMM protein was responsible 
for this phenomena and this protein was called UCP [11, 14]. UCP activity in BAT is sensitive to 
stimuli from cold exposure and diet. In BAT, cold stress and over feeding triggers β-adrenergic 
stimulation of lipolysis. This increases the free fatty acid concentration in BAT and relieves UCP 
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of nucleotide inhibition. In turn, UCP-mediated proton leakage is activated and results in less 
ATP production while the metabolic transformation of substrates required for ETC is released as 
heat [15, 16]. As a result, the role of this UCP was extended to the control of body weight and 
obesity [17].  
Upon discovering other UCP homologues in 1997, the UCP found in BAT was renamed 
UCP1 [18].  UCP2 has 59% sequence identity to UCP1 and is found in various tissues including 
pancreatic β-cells, liver, kidney and cerebellum [18]. UCP2 is proposed to influence glucose 
stimulated insulin secretion in pancreatic β-cells and regulate reactive oxygen species (ROS) 
production in the mitochondria [19, 20]. UCP3 has 57% sequence identity to UCP1 and is 
predominantly found in skeletal and heart muscle [21]. UCP3 is hypothesized to regulate ROS 
production, FA transport, and glucose metabolism in skeletal muscle [21, 22]. The most recently 
discovered homologues, UCP4 and UCP5, are found in the central nervous system with 30% and 
34% sequence identity to UCP1 respectively [16, 23, 24]. Their physiological roles include 
regulation of neuronal calcium secretion and reduction of reactive oxygen species [16, 23, 24]. 
 
1.3. Structure of Uncoupling Proteins  
Although five UCP homologues have been identified, their detailed structure at high 
resolution is yet to be elucidated. This is because membrane proteins need a membrane 
environment to maintain their structure and function [25]. In vitro studies of membrane proteins 
require disruption of the membrane microenvironment around the proteins. This process makes it 
tedious to appropriate samples to perform high-resolution x-ray crystallization or NMR  
studies [25]. Despite these limitations, the structure of UCPs is proposed to be similar to a 
member of the mitochondria anion carrier family (MCF) protein, ADP/ATP carrier protein 
(AAC) (Figure 3A) with which it has ~23% sequence identity [16]. UCPs and AAC share a 
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common tripartite structure that consists of three pseudo-repeat domains. Each domain contains 
two transmembrane (TM) α-helices that are joined by loops oriented towards the mitochondrial 
matrix [16]. Similar to the hypothesized structure, the NMR resolved structure of UCP2 has six 
TM helices that spans the IMM with the N- and C- terminus located in the IMS (Figure 3B) [26].  
However, structural differences exist between AAC and UCP2 including: the helix near the  
C-terminus of UCP2, the densely packed helices in AAC, and the more open matrix oriented 
helices in UCP2 (Figure 3A and 3B) [26]. 
 Sequence alignment analysis found a common MCF motif in UCPs and AAC: 
Px[D/E]xx[R/K] on TM helices 1, 3, 5, and [F/Y][D/E]xx[R/K]  located on TM helices 2, 4, and 
6 [27]. Apparently, the prolines in the motif form a kink in the odd helices for substrate binding 
while the charged residues form a salt bridge network that mediates substrate transport through 
the proteins [27]. 
 
A)                                                                         B) 
           
 
 
Figure 3: Structural similarity between ADP/ATP carrier protein and UCP2.                     
ADP/ATP structure (A) was determined with x-ray crystallography [29] while the UCP2 
structure (B) was resolved with NMR fragment searching [26]. Lateral view of both structures 
show six α-helices numbered H1-H6 that span the inner mitochondrial membrane are connected 
by loops located in the matrix. The structures were viewed in PyMOL [94] using accession 
numbers 2C3E and 2LCK1 from protein data bank respectively.  
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1.4. Uncoupling Protein 2 
UCP2 is a 33kDa protein that has the largest tissue distribution amongst all UCPs. High 
levels of UCP2 mRNA are detected in many tissues including heart, skeletal, BAT, kidney, liver, 
and the central nervous system. However, the protein has only been found in pancreatic β-cells, 
spleen, and hypothalamus, which imply a tight regulation of UCP2 at the translational  
level [9, 18].  
Since UCP2 has a high sequence identity to UCP1, researchers initially assumed the main 
role of UCP2 was thermogenesis. But experimental evidence showed that mice with their UCP2 
knocked out was insensitive to cold and diet induced thermogenesis [29]. This implied that 
thermogenesis was not the main function for UCP2 [29].  
Further research associated the UCP2 activity to the regulation of ROS production. In the 
mitochondria, 70–80% of ROS are produced as superoxide radical anions (O2
.-
) by Complex III 
in the ETC [30]. These superoxide anions are highly reactive and can cause oxidative stress. 
Oxidative stress is linked to aging and neurodegenerative diseases like Alzheimer’s and 
Parkinson’s [9]. Although the mitochondria have a unique set of antioxidant enzymes that 
removes superoxide radicals, UCP2 mediated proton leakage could also decrease superoxide 
anion production in the mitochondria. A high membrane potential results in the formation of 
superoxide anion at complexes I and III [30]. Therefore, the dissipation of the electrochemical 
gradient by UCP2 decreases the membrane potential thereby reducing ROS production [9, 30].  
 In addition, UCP2 activity is also linked to the immune response in macrophages. One 
study showed that mice macrophages with knocked out UCP2 survived longer when infected 
with Toxoplasma gondii parasite compared to mice with functional UCP2 [31, 32]. UCP2 is also 
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proposed to play a role in obesity, cancer and regulation of insulin secretion in β cells, obesity 
and cancer [20].  
 
1.5. Ion Transport and Nucleotide Inhibition in UCPs. 
Despite the proposed physiological roles of UCPs above, the mechanism of proton 
leakage by UCPs is still debated. So far, three main mechanisms of proton transport have been 
proposed for UCPs: the fatty acid (FA) cycling model [33], cofactor model [34], and shuttling 
model [35]. The FA cycling model states that UCPs transport FA anions from the matrix into the 
intermembrane space, where it accepts a proton and flip-flops across the IMM into the matrix. 
Once in the matrix, the FAs release the protons and the FA anion is transported back to the 
intermembrane space via UCP to repeat the cycle (Figure 4A) [33]. In contrast, the cofactor 
model states that FA bind to UCPs and uses its carboxylate anion to transport protons from the 
intermembrane space to UCPs ionizable amino acid residues, and finally into the matrix      
(Figure 4B) [34]. Recently, a FA shuttling model was proposed in which FA anions bind to UCP 
via their hydrophobic chain.  UCP transports the FA anion towards the intermembrane space to 
get protonated. After which, UCP simultaneously transports the FA and proton towards the 
matrix. However, the FA remains bound to the protein after releasing the proton, and UCP 
transport’s the FA anion for another translocation cycle (Figure 3C) [35]. Unfortunately, multiple 
experiments have refuted each of the competing models, making it difficult to deduce a specific 
mode of transport for UCPs. 
Though it is generally accepted that FAs activate UCP proton transport, current research 
has indicated that ROS also activate UCP uncoupling activity. It is proposed that ROS oxidize a 
specific cysteine thiol residue and results in FA displacement of nucleotides and activation of 
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FA-mediated uncoupling in UCPs. Furthermore, mutation of this cysteine residue desensitized 
UCP1 to purine inhibition [36]. 
In vitro studies show that UCPs also transport small anions such as chloride (Cl
-
), nitrate 
(NO3
-
), and alkylsulfonates (R-SO3
-
). Mutagenic studies revealed amino acids in TM 2 of UCP1 
can be responsible for Cl
-
 transport [39]. In addition, FAs are suggested to competitively inhibit 
UCP Cl
-
 transport [37-39].   
It is also known that UCPs are inhibited by purine di- and tri-phosphate nucleotides 
(ATP, ADP, GTP, GDP). Site directed mutagenesis identified arginine and glutamate residues in 
UCP1 that are involved in binding purine nucleotides [16]. The arginine residues bind the sugar 
moiety and phosphate groups of the nucleotide while glutamate stabilizes these interactions [16]. 
Although, there is ample information to support UCPs proton transport, anion transport and 
nucleotide inhibition, more research must be performed to establish the mechanism of these 
processes and their potential correlation to each other [9, 16].  
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Figure 4: Proposed mechanisms for fatty acid mediated proton transport by UCP. 
 A) Cycling model: FA anions are transported by UCPs into the intermembrane space (IMS). 
There, the FA anion becomes protonated, flip flops across the inner mitochondrial membrane 
(IMM) and releases the protons into the mitochondrial matrix (MM).  B) Cofactor model: FA 
anions bind to specific sites on UCP and accepts protons from the IMS. This proton is buffered 
through UCP via its ionisable side chains into the MM. C) Shuttling model: FA anion binds to 
UCP and is translocated towards the IMS to accepts a proton. The UCP then translocates the 
protonated FA towards the MM where the proton is released but the FA remains bound to the 
protein. Stephanie Uwumarenogie created this image with the Microsoft paint application. 
 
 
1.6. Conserved Motifs in Members of Mitochondrial Carrier Family 
Resolving the x-ray crystal structure of AAC led researchers to confirm motifs in the 
protein that are also conserved amongst the MCF. Sequence analysis identified a highly 
conserved cytoplasmic and matrix network motif in AAC and some MCF proteins including 
UCPs [40]. The cytoplasmic motif [F/Y][D/E]xx[R/K] (on even numbered helices) is positioned 
towards the intermembrane space while the matrix motif PX[D/E]Xxx[R/K] (on odd numbered 
helices) is located towards the matrix side of the membrane [40 - 42]. Mutating the positively 
and negatively charged residues to uncharged amino acids in the matrix motif of yeast AAC 
revealed charged pair interactions between amino acid residues in the matrix network [40]. 
Furthermore, mutating the charged amino acid residues in the cytoplasmic network of 
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oxoglutarate transporter (member of MCF) to cysteine showed decreased transport rate up to 
15% compared to wild type [43]. These studies suggested that the charged residues in both 
motifs might influence substrate binding and the mechanism of transport in AAC and other 
members of the MCF [42, 43].  
Symmetry analysis and the measurement of interaction energies between amino acids in 
both networks of AAC and UCPs, revealed that charged amino acids in the cytoplasmic network 
form salt bridges between TM 2, 4, and 6 while the charged amino acids in the matrix network 
form salt bridges between TM 1, 3, and 5 (Figure 5) (Figure A1) [42, 44]. In proteins, salt bridge 
interactions are defined as non-covalent interactions between oppositely charged amino acids 
that play vital roles in protein folding, substrate binding and transport [45].  In 2006, Robinson 
and Kunji [42] proposed a mechanism of substrate translocation that involved the formation and 
disruption of the cytoplasmic and matrix salt bridge networks in MCF proteins. The proposed 
mechanism stated that when a substrate was bound to the central cavity of the MCF protein, a 
conformational change was induced in the protein. This conformational change enabled the 
charged residues in the cytoplasmic network to form a salt bridge that closed the protein toward 
the intermembrane space. Concurrently, the matrix salt bridge was disrupted so that the substrate 
was released into the matrix. Meanwhile, when a substrate was exported out of the matrix, the 
matrix salt bridge network was formed while the cytoplasmic salt bridge network was disrupted 
[42]. On this basis, the charged residues in the cytoplasmic and matrix salt bridge network could 
play an important role in the ion transport mechanism of MCF proteins including UCPs. 
 In the cytoplasmic network of UCP2, K104 (TM2) and K295 (TM6) form a salt bridge 
interaction with D198 (TM4) and D101 (TM2) respectively (Figure 6A). While in the matrix 
network K38 (TM1), K141 (TM3), and K239 (TM5) form a salt bridge interaction with D236 
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(TM5), D35 (TM1), and D138 (TM3) respectively (Figure 6B) [42]. However, the effect that the 
charged residues in both networks may have on ion transport mechanism of UCP2 has not been 
proven experimentally. Therefore, in this study, the role that positively charged lysine residues in 
the matrix salt bridge network have on the ion transport activity of UCP2 was investigated.  
 
 
Figure 5: Side view of the charged amino acids in the cytoplasmic and matrix network of 
UCP2. Positively charged lysine (K) and negatively charged aspartate (D) amino acids in both 
networks are highlighted in blue and red respectively. The transmembrane helices are numbered  
1 – 6. Charged residues in the cytoplasmic network are highlighted by the big oval while the 
small oval highlights the cluster of charged residues in the matrix network. The sizes of the oval 
differ because the structure was resolved with GDP bound which locked the protein in a state 
that was open to the intermembrane space and closed toward the mitochondrial matrix.  The 
NMR resolved structure of UCP2 structure was viewed in PyMOL [94] using accession number 
2LCK1 from the protein data bank. 
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Figure 6: Proposed cytoplasmic and matrix salt bridge interactions in UCP2. Positively 
charged lysines are highlighted in blue while negatively charged aspartate amino acids are 
highlighted in red. The dashed line represents the proposed salt bridge interaction between 
oppositely charged amino acids in the networks. A) Salt bridge interactions between lysine and 
aspartate residues in TM 2, 4 and 6 in the cytoplasmic network; B) Salt bridge interactions 
between lysine and aspartate residues in TM 1, 3 and 5 in the matrix network.  The amino acids 
in the networks were viewed from the cytosolic side (top view) of the NMR resolved structure of 
UCP2 protein. The UCP2 structure was viewed in PyMOL [94] using accession number 2LCK1 
from the protein data bank.  
 
A) 
B) 
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1.7. Research Objectives 
 The overall objective of this research project was to further understand the mechanism of 
ion transport in UCP2. To achieve this objective, point mutations were introduced into the matrix 
network of UCP2 cDNA to specifically probe the role of lysine residues in this network on the 
ion transport mechanism of the protein. The lysine residues in the matrix network were replaced 
with glutamine to eliminate the positive charge required for a salt bridge interaction with the 
negatively charged aspartate amino acid residues in the network. Past studies showed that the 
proton transport activity of UCPs are activated by free FAs and inhibited by purine di- and tri-
phosphate nucleotides [7, 46]. Therefore, the effect of the mutations on the proton transport rate 
of UCP2 in the presence and absence of purine nucleotides could determine the role of lysine 
residues in the matrix salt bridge network on the proton transport mechanism and possibly 
nucleotide binding activity of UCP2.  
 Due to the proposed role of the matrix salt bridge network on substrate translocation in 
MCF proteins [42], it was expected that the mutations would destabilize the matrix salt bridge 
network and diminish the proton transport activity of UCP2. Furthermore, since the amino acid 
residues involved in nucleotide binding are located near the matrix salt bridge network of UCP2 
(Figure 7), these mutations could also alter the nucleotide binding site and either enhance or 
decrease nucleotide inhibition of FA-mediated proton transport in UCP2.  
To achieve the above objective, the following steps were successfully performed: Firstly, 
the lysine residues at positions 38, 141, and 239 in the matrix network of UCP2 were changed to 
glutamine using site directed mutagenesis. More specifically, overlap extension polymerase 
chain reaction (PCR) technique was utilized to introduce three single mutations and a double 
mutation into the UCP2 cDNA. Secondly, the mutant and wild type UCP2 proteins were 
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expressed in and further isolated from the inner membranes of Escherichia coli (E.coli). After 
which the dominantly monomeric proteins were purified with immobilized metal affinity 
chromatography (IMAC). Thirdly, far-UV circular dichroism (CD) was used to determine the 
overall conformation of the mutant and native UCP2 proteins. In the final step, a fluorescence-
based assay was used to measure the proton transport activity of  UCP2 and its mutants in the 
presence and absence of ATP. Overall, experimental results from this project could expand our 
knowledge on the mechanism of ion transport in UCP2 and other UCP homologues.  
A detailed explanation of the molecular biology and biophysical techniques used in this 
project are described in subsequent sections.  
 
 
Figure 7: Arginine residues involved in nucleotide binding in UCP2. Arginine residues (R88, 
R185, and R279) are highlighted in green, while the blue and red colours highlight the lysine and 
aspartate residues in the UCP2 matrix network. The dashed line represents the proposed salt 
bridge interaction between oppositely charged amino acids in the matrix network. A) Side view 
of the nucleotide binding arginine residues and the matrix network. B) Cytosolic view (top view) 
of the arginine residues and matrix salt bridge network. The UCP2 structure was viewed in 
PyMOL [94] using accession number 2LCK1 from the protein data bank.  
A) B) 
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CHAPTER 2: MOLECULAR BIOLOGY AND BIOPHYSICAL 
TECHNIQUES USED TO STUDY THE STRUCTURE AND 
FUNCTION OF MEMBRANE PROTEINS 
2.1. Overlap Extension Polymerase Chain Reaction (PCR) 
 To investigate the role that positively charged residues in the matrix network had on the 
ion transport activity of UCP2, the lysine residues at positions 38, 141, and 239 were changed to 
glutamine. Glutamine was chosen to replace lysine because they are relatively similar in size and 
structure. However, the uncharged nature of glutamine ensured the salt bridge interaction 
between lysine and aspartate in the matrix network was disrupted so that the effect of the 
mutations on transport activity of UCP2 could be measured.  
In total, three single mutants and one double mutant UCP2 cDNAs encoded the proteins: 
K38Q, K141Q, K239Q and K38Q/K239Q. The mutations were inserted into the cDNA UCP2 
cDNA using overlap extension PCR. In this technique, mutations were introduced into the UCP2 
cDNA with mutagenic primers in two separate PCR reactions [47]. In a third PCR reaction, the 
DNA fragments from the reactions were made single stranded and the overlapping region 
enabled the products from each reaction to hybridise and form the final nucleotide sequence with 
the targeted mutation. [47]  
More specifically, the first PCR reaction required a sense flanking primer (A) that 
hybridized to the end of the UCP2 cDNA, and an antisense mutagenic primer (B) that contained 
the mismatched bases and hybridized to the mutation site [47]. Attached to the end of primer A, 
was an NcoI restriction site that enabled the insertion of the mutated cDNA into an expression 
vector, as well as a polyhistidine-tag (His-tag) that allowed the purification of the expressed 
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protein with IMAC. Similarly, the second PCR reaction involved an antisense flanking primer 
(D) that hybridized and added a HindIII restriction site to the other end of the cDNA, as well as a 
sense mutagenic primer (C) which hybridized to the site of the cDNA to be altered [47, 48]. In 
the final PCR reaction, the PCR products AB and CD from the first and second reactions were 
denatured and annealed which enabled overlapping strands to hybridize. The overlapping hybrid 
strands containing a 3’-hydroxyl group, were extended by DNA polymerase to form the cDNA 
product with the appropriate mutation. The mutated cDNA was further amplified in several PCR 
cycles with the flanking primers (A and B) (Figure 8) [47, 48]. Each mutated cDNA product was 
cloned into an expression vector for transformation into bacterial cells.  
 
 
Figure 8: An illustration for the process of overlap extension polymerase chain reaction. 
Primers B and C represent the mutagenic primers while primers A and D are the flanking 
primers. Retrieved with permission from Nature [48], copyright 2007.  
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2.2. Cloning, Protein Expression, and Purification 
 
Once the UCP2 mutant cDNAs were produced, the cDNA products were cloned into a 
pET26b(+) vector. The pET26b(+) vector was chosen because it encoded the antibiotic 
resistance gene for kanamycin and also a pelB signal peptide. The signal peptide targeted the 
expressed mutant proteins towards the periplasmic space as a means to allow the proteins fold  in 
the bacteria inner membrane [49, 50]. To clone the cDNA into the pET26b(+) vector, both 
components were digested with NcoI and HINDIII restriction enzymes to create sticky ends. The 
sticky ends allowed the ligation of theDNA into pET26b(+) using T4 DNA ligase enzyme and 
formed a recombinant vector (Figure 9) [51]. Next, the recombinant vector was transformed into 
E.coli cells through heat shock. During heat shock, chemically competent bacteria cells were 
exposed to cold and hot temperatures to briefly disrupt the bacteria membrane to take up the 
recombinant vector (Figure 9) [51]. After transformation, the recombinant proteins were 
expressed via auto-induction, where lactose and glycerol served as carbon sources after glucose 
was consumed by the bacterial cell [52]. The expressed proteins were isolated from bacteria 
membranes and purified with IMAC.  
In the next step, the protein’s purity and relative molecular mass was assessed with a 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE is a 
method whereby proteins are denatured and separated by size [53]. Protein separation is achieved 
by the difference in their migration rates through a gel matrix that is composed of crosslinked 
acrylamide polymers [53]. In this technique, an anionic detergent called SDS linearized the 
folded state of the protein and gave the polypeptide chain an overall negative charge. Once, the 
denatured protein was applied onto the SDS gel, an electric current was applied that allowed 
proteins to move through the gel matrix according to their size [53, 54]. After the size and purity 
 19 
 
of each protein were confirmed, the proteins were further identified using a western blot 
technique [55].  In this method, the proteins resolved on an SDS-PAGE gel were transferred onto 
a nitrocellulose membrane, and incubated with a polyclonal antiUCP1/2/3 primary antibody that 
bound to a specific UCP2 sequence on the proteins. After the unbound antibodies were washed 
off the membrane, the bound antibodies were detected with a secondary antibody linked to an 
enzyme that cleaved a chemiluminescent agent. The illuminescent product was visualized on an 
imager and the detected band corresponded to the identified protein [55]. 
 
 
 
Figure 9: Cloning UCP2 gene into pET26b(+) vector. The UCP2 mutant genes were 
synthesized with an NcoI and HindIII site for ligation into the pET26b(+) plasmid. The 
recombinant vector was transformed into E.coli cells for protein expression. Stephanie 
Uwumarenogie created this image on Microsoft paint. 
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2.3. Reconstitution of Membrane Proteins into Phospholipid vesicles 
In vitro studies of integral membrane proteins rely on proper incorporation of these 
proteins into lipid bilayers to ensure they maintain their native folded state [56]. In 
reconstitution, membrane proteins are inserted into phospholipid vesicles (liposomes) to mimic 
the protein’s interaction with cellular membranes. Proper reconstitution of membrane proteins 
into liposomes is essential for their structural and functional studies [56].   
Liposomes are composed of one (unilamellar vesicles) or more (multilamellar vesicles) 
phospholipid bilayers that enclose an aqueous compartment [56]. Liposomes are made when 
phospholipids that form bilayer structures are dispersed in aqueous solution, and spontaneously 
associate in aqueous media [56]. This association is favoured because the hydrophobic acyl 
chains are buried in the hydrophobic center while the hydrophilic head groups interact with the 
aqueous solvent [56]. In addition, the edges of the phospholipid bilayer are sealed to form 
vesicles to ensure the acyl chains are not exposed to the aqueous solution [56]. Liposomes can be 
used to administer drugs, and study the folding and ion transport properties of membrane 
proteins [56]. Liposomes embedded proteins are known as known as proteoliposomes [56]. 
 Liposomes can be small unilamellar vesicles (SUVs) with diameters of 20 nm – 50 nm. 
Due to the small size and high curvature, SUVs tend to fuse to form larger vesicles [56, 57]. 
Meanwhile, large unilamellar vesicles (LUVs) with diameters from 100 nm to 1 μm [56], are 
desired for most reconstitution studies because of their decreased curvature that implies better 
stability for ion transport assays across and other biophysical studies [56, 57].  
Reconstitution of integral membrane proteins into liposomes can be accomplished 
through different techniques, including: reverse-phase evaporation, sonication, and detergent-
mediated reconstitution [57]. In reverse-phase evaporation, phospholipids, membrane proteins, 
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and an aqueous buffer are mixed in excess organic solvent. Evaporating the organic solvent from 
the emulsion results in the formation of proteoliposomes [57, 58]. During sonication, 
phospholipids and membrane proteins are rehydrated in aqueous buffer. The phospholipid and 
protein suspension forms multilamellar vesicles (MLVs) with proteins embedded in the bilayers 
which are ultimately are broken into SUVs with sonic energy [59]. A limitation of both 
techniques is that the organic solvent in reverse-phase evaporation and high pressure from 
sonication often denature the membrane proteins [57, 59].  
To avoid the above-mentioned complications, detergent-mediated reconstitution was the 
method used in this project. In this method, a dry phospholipid film is rehydrated in aqueous 
solvent to form MLVs, followed by solubilisation in detergent to form mixed micelles [57]. The 
purified membrane protein (already solubilized in a detergent) is then added to the mixed micelle 
to form a lipid-protein-detergent mixed micelle complex [57].  Detergent is removed with 
dialysis for detergents with high critical micelle concentration (CMC) or by hydrophobic 
adsorption onto polystyrene beads. Detergent removal from the lipid-protein-detergent mixtures 
allows the protein to incorporate into LUVs [57].  
 Overall, protein reconstitution into liposomes is a vital step for studying the biophysical 
properties of proteins outside the cell membrane. However, liposome size and homogeneity must 
also be assessed to ensure results from such studies are accurate and reproducible. 
     
2.4. Analysis of Liposome Size Distribution and Stability with Dynamic Light 
Scattering 
 Dynamic light scattering (DLS) is technique often used to study protein aggregation, 
ligand binding to macromolecules as well as the size and homogeneity of liposomes [60, 61].  
DLS measures the size distribution of particles that experience Brownian motion in a liquid [60]. 
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Brownian motion describes the random movement of particles suspended in a medium, due to 
collisions between the particles and molecules in the medium. As a result, Brownian motion in 
larger particles is slowed down compared to smaller particles [60]. DLS correlates the intensity 
of scattered light by particles in Brownian motion to the size of particles in a sample [60].  
 In DLS technique, a sample is illuminated with a polarized beam of light from a laser 
source. The incident light is scattered in different directions upon contact with the surface of the 
particle in the sample [61]. A detector measures the intensity of scattered light by the sample and 
transferred to a correlator [61]. The correlator compares the level of similarity between two 
intensities measured at different time points. Furthermore, this comparison is used to determine 
the rate at which the intensity of scattered light fluctuates over time [61]. Due to Brownian 
motion, smaller particles fluctuate the scattered light intensity at faster rates compared to larger 
particles [60, 61]. Furthermore, the size distribution of the sample is can be determined from a 
Gaussian distribution curve of percent intensity of light scattered versus size of particle. [62]. A 
narrow width curve indicates a monodisperse sample while a wide width curve shows a 
polydisperse population of particles in the sample [62].  
 
2.5. Analysis of Protein Secondary Structure with Circular Dichroism 
Spectroscopy 
Circular dichroism (CD) is the difference in the absorption of left- and right-handed 
circularly polarized light by chiral chromophores [63]. Chirality is either an intrinsic property of 
chromophores or induced in them when subjected to a chiral environment.  
CD spectroscopy is a technique often used to estimate the average secondary structure of 
proteins [63].  CD spectra of proteins are measured with a spectropolarimeter. A CD 
spectrometer uses a high-energy xenon light source to radiate circularly polarised light through a 
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modulator, which splits it into left- and right-handed circularly polarised light. When an optically 
active molecule preferentially absorbs one form of the polarised light over the other, the detected 
emitted light is the difference between the two and is shown as ellipticity.  The CD spectrum for 
the molecule is generated as changes in ellipticity (θ) in millidegrees versus changes in 
wavelength [63].  
In the far-UV range (260 – 180 nm) the differential absorption of circularly polarised 
light by the protein’s backbone peptide bonds yields CD spectra. Absorption in this wavelength 
range is mostly due to nπ* or ππ* transitions [63]. Each protein secondary structure shows a 
distinct CD spectrum because the peptide bond chromophores are oriented differently. As a 
result, the bonds absorb at different wavelengths with varied intensities which gives rise to 
distinct spectra [63]. Thus, far-UV CD can estimate the overall α-helix, β-sheet, or disordered 
structure of a protein (Figure 10) [63]. In contrast, CD spectrum in the near-UV region (260 – 
320 nm) detects the local environment of protein aromatic side chains and disulfide bonds, which 
provides information on the tertiary structure of the protein [63]. In addition, CD spectroscopy 
can also monitor changes in a protein’s secondary structure at different temperatures, pH or 
interaction with ligands. Overall, CD spectroscopy offers a fast and reliable way to determine 
secondary structure of soluble proteins in aqueous solutions as well as membrane proteins in 
detergent and liposome systems.  
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Figure 10: Far-UV CD spectra for protein secondary structures: the solid line represents an 
α-helix; the dashed line represents an antiparallel β-sheet; the dotted line represents the type I β-
turn; and the dots and short dashed line represents a random coil [63].  
 
2.6. Fluorescence Based Ion Transport Measurements across Reconstituted 
Vesicles 
Fluorescence spectroscopy is a technique that is widely used to study the fluorescent 
properties of biomolecules [64]. Fluorescence is a phenomenon in which light of a particular 
wavelength is absorbed by electrons in a molecule. Upon light absorption, the electrons are 
excited from a vibrational energy level in the ground state to a higher vibrational energy  
level [65]. Some of the energy from the excited electron is lost as they move to the lower 
vibrational levels of the excited state. Finally, the electrons return to the ground state within 10
-12
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to 10
-9
 s, and in the process residual energy is emitted as a photon at a longer wavelength [65]. 
Fluorescence spectroscopy can therefore, analyze the structural, and functional interactions of 
molecular systems [64, 65]. 
Proteins have intrinsic fluorophores such as the amino acids: tryptophan, phenylalanine 
and tyrosine, and sometimes, an extrinsic fluorophore like dansyl-chloride that is covalently 
attached to the protein [65]. Tryptophan's sensitivity to the polarity of the local environment 
around it makes it a useful target for fluorescence spectroscopy to study protein dynamics [65]. 
Thus, a spectral shift in tryptophan's emission may be due to protein folding or unfolding, as well 
as protein ligand and protein-protein interactions [65].  
Fluorescence quenching is a process where the fluorescence intensity of a sample is 
decreased upon interaction of the fluorophore with a quenching agent [65]. Static and dynamic 
quenching are considered to be the two main types of fluorescence quenching [65]. In static 
quenching, a complex is formed at the ground state when the fluorophore and quencher make 
contact. As a result, when the complex is excited, it returns to the ground state without the 
emission of light (non-fluorescent) [65]. On the other hand, dynamic quenching is observed 
when a quencher collides with the fluorophore in its excited state. Upon contact, the energy 
released by the excited fluorophore is transferred to the quencher and therefore, no light is 
emitted by the fluorophore when returned to the ground state [65]. Commonly used dynamic 
quenchers are, oxygen, acrylamide and halogens [65]. With fluorescence quenching the topology 
of a protein or biological membrane can be probed. This is based on the accessibility of the 
fluorophore, tagged to a protein or phospholipid, to the quenching agent [65].  
 Fluorescence quenching technique was also used to develop an assay that can measure 
proton transport across liposomes [66]. This assay indirectly measured the proton flux with the 
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fluorescent probe 6-methoxy-N-(3-sulfopropyl) quinolinium (SPQ) [66]. SPQ is a fluorescent 
dye that is dynamically quenched by halides and anionic forms of zwitterionic buffers like 
tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES – pKa 7.5) (Figure 11) [66]. At 
low pH, the TES buffer is predominantly protonated and does not quench SPQ. However, at high 
pH, TES is mostly in its anionic form and quenches the SPQ signal [66]. SPQ is used to directly 
detect changes in the concentration of buffers, and indirectly, the change in total acidity (or 
proton concentration) which is related to proton flux [66].  SPQ quenching by TES, was 
employed in this study to indirectly measure the rate of proton transport by native and mutant 
UCP2 proteins. 
 
 
Figure 11: Structure of 6-methoxy-N-(3-sulfopropyl) quinolinium (SPQ). SPQ quenching by 
TES anion was used to indirectly measure the proton flux by native and mutant UCP2 proteins. 
This image was retrieved from [67]. 
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CHAPTER 3: MATERIALS, EXPERIMENTAL DESIGN AND 
METHODS 
3.1. Materials 
 All primers were ordered from Invitrogen
TM
 (Massachusetts, USA). Wizard Plus SV 
Miniprep DNA Purification System was obtained from Promega (Wisconsin, USA). HotStar 
HiFidelity DNA polymerase kit was purchased from Qiagen (Germany).  E.Z.N.A Gel 
Extraction Kit was purchased from OMEGA Bio-tek (Georgia, USA). DNA sequencing was 
performed at The Centre For Applied Genomics (TCAG) Sequencing Facility (Toronto, 
Canada). 10x CutSmart Buffer, NcoI-HF and HindIII-HF Restriction Enzymes, 10x Ligase 
buffer with 10mM ATP and T4 DNA Ligase were all purchased from New England BioLabs 
(NEB) (Massachusetts, USA). All other chemicals used for transformation into E.coli cells and 
protein expression were purchased from Bioshop (Canada). Complete protease inhibitor cocktail 
tablet EDTA-free was purchased from Roche Applied Science (Indianapolis USA). 
Lauryldimethylamine-oxide (LDAO) was ordered from Sigma-Aldrich Life Sciences (Missouri, 
USA), n-octyl-β-D-glucopyranoside (OG) was obtained from Anatrace (California, USA), 
nickel-nitrilo-triacetic acid-agarose beads (Ni-NTA) were purchased from Thermo Scientific 
(Massachusetts, USA), tris(hydroxypropyl)phosphine (THP) was ordered from EMD Milipore 
(Massachusetts, USA), Sephadex G25-300 (Coarse) desalting columns were obtained from GE 
Healthcare (UK). Rabbit antiUCP1/2/3 and goat anti rabbit antibodies were obtained from Santa 
Cruz (Dallas, Texas). L-α-Lecithin, composed of at least 60% phosphatidylcholine while the 
other 40% consisted of phosphatidylethanolamine with trace amounts of cholesterol and 
triglycerides, was ordered from Sigma-Aldrich (Missouri, USA). 6-Methoxy-N-(3-sulfopropyl)-
quinolinium (SPQ) was purchased from Biotium Inc. (California, USA). Sodium palmitate acid 
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and purine nucleotide (ATP) was obtained from Sigma Aldrich (ON, Canada). SM-2 Biobeads 
were obtained from Bio-Rad (ON, Canada) while Sephadex G25-300 (Coarse) resins were 
purchased from GE Healthcare (QC, Canada). Nigericin and valinomycin were purchased from 
Sigma (ON, Canada) and stored in 100% ethanol at -20
o
C. 
 
3.2. Experimental Design and Methods         
3.2.1. Site Directed Mutagenesis by Overlap Extension PCR  
 The first phase of this project was to introduce point mutations into the UCP2 cDNA and 
clone the mutated cDNA's into a pET26b(+) vector with overlap extension PCR . Three single 
mutant cDNAs encoded the proteins: K38Q, K141Q, and K239Q, and a double mutant cDNA 
encoded the protein: K38Q/K239Q. The wild type N-terminally, His-tagged UCP2 cDNA that 
was used as a template for all mutations was cloned into a pET26b(+) vector with its endogenous 
NcoI knocked out, as described previously [68]. In overlap extension PCR, two separate rounds 
of PCR that consist of the template, a flanking primer and a mutagenic primer, created two 
cDNA fragments with overlapping ends. In a third PCR reaction, the products from both 
reactions served as a template for the flanking primers to amplify the cDNA with the desired 
mutation [47].  
More specifically, the recombinant vector (pet26b(+):UCP2) that contained the native 
UCP2 cDNA was isolated from DH5α E.coli cells. The DH5α cells were grown in 10 mL LB 
broth that contained 50 μg/mL kanamycin (kan) at 37 oC, 240 rpm, for 18 h in a shaking 
incubator.  The pet26b(+) vector with the wild type UCP2 cDNA, was extracted from DH5α 
cells with a Wizard Plus SV Miniprep DNA Purification System as described in the protocol  
in [69].  Upon which, the isolated recombinant vector was used as a template for the initial two 
rounds of overlap extension PCR reactions. For the first PCR reaction, an antisense mutagenic 
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primer, as well as a sense flanking primer that had an NcoI restriction site attached at the 5’ end, 
were incubated in a thermocycler under specific conditions to produce the first overlapping 
cDNA fragment.  Similarly, a second PCR reaction that involved the sense mutagenic primer, 
and an antisense flanking primer with a HindIII restriction site attached to the 3’ end, were used 
to prepare the second cDNA fragment. The resulting cDNA products from both PCR reactions 
were run on a 1% agarose gel, at 120V for 1hr, and visualized on a UV transilluminator to 
confirm the cDNA's with the required length of nucleotide sequence were produced. Next, the 
PCR products were purified from the gel with an E.Z.N.A Gel Extraction Kit [70]. In the final 
PCR reaction, the PCR products from both reactions hybridized at the overlapping segments, 
which are extended by DNA polymerase and further amplified by flanking primers to produce 
the full-length cDNA with the required mutation.  
To create the double mutant cDNA, overlap extension PCR along with the appropriate 
mutagenic primers was used to generate a full-length cDNA with the first mutation. This cDNA 
served as the template for another overlap extension PCR that introduced the second mutation 
into the cDNA. 
All PCR reactions were performed with a HotStar HiFidelity DNA polymerase kit 
(Qiagen) and were prepared in dome capped PCR tubes [71]. The mutant cDNA's were produced 
with PCR components and thermocycler conditions listed in Tables 1 and 2. In addition, Table 3 
provides the nucleotide sequence for the flanking and mutagenic primers utilized in the PCR 
reactions.  
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Table 1: Reaction composition by overlap extension PCR: Volume of the components used in 
PCR reaction to produce each mutant UCP2 cDNA.  
 
Components PCR Reaction #1 and #2 PCR Reaction #3 
5x HotStar HiFidelity PCR 
Buffer 
10 μL 10 μL 
100μM Flanking Primer 0.5 μL 0.5 μL (for each sense and 
antisense) 
100μM Mutagenic Primer 0.5 μL -------- 
HotStar HiFidelity DNA 
Polymerase  
1 μL 1 μL 
RNase-free Water 3 μL 34 μL 
Template DNA (50 ng) 2 μL (isolated pET26-
UCP2wt) 
2 μL PCR product #1 +                
2 μL PCR product #2 
 
Total Volume 50 μL 50μL 
 
Table 2: Thermocycler Conditions for All PCR Reactions: The overlap extension PCR 
reaction required specific temperatures for the cycling steps to efficiently produce the mutant 
cDNA's. 
 
Cycling Steps
∆
 Temperature Time 
Initial Denaturation 95 
o
C 5 minutes 
Denaturation 94 
o
C 15 seconds  
Annealing* 63 
o
C  30 seconds 
Extension 72 
o
C 1 minute 
Final Extension 72 
o
C 10 minutes 
Hold 12 
o
C Infinite 
∆
Denaturation, annealing and extension steps were repeated for 35 cycles. 
* For K141Q, the annealing temperature for 2
nd
 PCR reaction was 65
o
C. 
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Table 3: Flanking and Mutant Primers designed for Site Directed Mutagenesis of UCP2 
Primer Type Primer Name Primers* 
Flanking Primer for 
UCP2wt and all 
mutants 
 
 
 
Sense primer with 
NcoI restriction 
enzyme site  
5’ GGAGATATACCCATGGGAGGATCGCATCACC 3’ 
Antisense primer 
with HindIII 
restriction 
enzyme site  
5’ CCGCAAGCTTGTCGACGGAGCTCTTAGAAGGG 3’ 
K38Q Mutagenic 
primer 
AAA:CAA 
Sense primer 5’ CCTCTGGATACTGCTCAAGTCCGGTTACAGATCC 3’ 
Antisense  primer  5’GGATCTGTAACCGGACTTGAGCAGTATCCAGAGG 3’ 
 
K141Q Mutagenic 
primer 
AAG:CAG 
Sense primer 5’ CCACGGATGTGGTACAGGTCCGATTCCAAGC 3’ 
Antisense  primer 5’ GCTTGGAATCGGACCTGTACCACATCCGTGG 3’ 
K239Q Mutagenic 
primer  
AAG:CAG 
Sense primer 5’CCCTGTAGACGTGGTCCAGACGAGATACATGAAC 3’ 
Antisense  primer 5’ GTTCATGTATCTCGTCTGGACCACGTCTACAGGG 3’ 
*The restriction enzyme sites in the flanking primer and the specific nucleotide bases changed in 
the mutagenic primers are highlighted and underlined. 
 
3.2.2. Ligation of UCP2 Mutant cDNA into pET26b(+) and Transformation 
into DH5α  
 Once all mutant cDNA's were prepared, the cDNA's were cloned into a pET26b(+) 
vector.  The mutant cDNA's were run on a 1% agarose gel and subsequently purified with the 
E.Z.N.A Gel Extraction Kit [57]. After which, an empty pET26b(+) vector was isolated from   
DH5α cells.  The empty pET26b(+)  and each mutant cDNA (2 μg of each component) were 
digested with NcoI-HF and HindIII-HF restriction enzymes. Restriction digest reactions were 
performed at 37 
o
C for 3 h in CutSmart buffer. The double digested products were excised from 
an agarose gel and purified with the E.Z.NA Gel Extraction Kit [70]. Each mutant cDNA was 
ligated into a pET26b(+) vector, in a ligation reaction that consisted of 300 ng cDNA, 60 ng 
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vector, 1 μL T4 DNA ligase enzyme, and 1 μL ligase buffer. These components were incubated 
in a 16 
o
C water bath for 16 h.   
 The ligated products were transformed into chemically competent DH5α cells through 
heat shock [72]. This was done by the addition of ~100 ng ligated DNA product to 100 μL DH5α 
competent cells, followed by incubation on ice for 30 min and heat shock at 42 
o
C for 90 s. After 
heat shock, the cells were allowed to recover on ice for 5 min. Next, the cells were diluted to  
900 μL with LB broth after which, the cells were grown for 37 oC, 240 rpm for 1 h. Thereafter, 
100 μL of transformed cells were grown overnight, on kanamycin (50 μg/ml) selective agar 
plates at 37 
o
C for 18 h.  
After overnight incubation of the transformed DH5α cells, three positive colonies were 
obtained from the selective media and grown in 10 mL LB and 50 μg/ml kanamycin at 37 oC, 
240 rpm for 16 h.  Upon cell growth, the recombinant vector with the appropriate mutant cDNA 
was extracted from cell culture via Wizard Plus SV Miniprep DNA Purification System [69]. In 
order to confirm that the isolated vectors had the cDNA incorporated, 1 μg of the recombinant 
vector was digested with NcoI-HF and HindIII-HF restriction enzymes at 37 
o
C for 3 h. The 
digested products were run on a 1% agarose gel stained with ethidium bromide, and viewed 
using a VersaDoc 4000 Gel Imaging System (Bio-Rad). Recombinant vectors were confirmed to 
contain the mutant cDNA if an ~5 Kilobase (kb) band that corresponds to the size of the vector 
and ~1.05 kb band for the cDNA was identified on the gel.  
Glycerol stocks were prepared for colonies that had the mutant cDNA by inoculating the 
cells into a 4 mL LB broth with 50 μg/ml kanamycin and grown at 37 oC for 16 h. Two glycerol 
stocks were made for each positive colony, with 500 μL of 50% glycerol and 500uL cell culture. 
The prepared glycerol stocks were stored at -80 
o
C. 
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3.2.3. Confirmation of Mutant cDNA Sequence and Transformation of the 
Recombinant Vector into BL21-Codon Plus-RIPL cells 
 Once the mutant cDNA's were successful cloned into the pET26b(+) vector, the next step 
was to confirm that the prepared mutant cDNA's, had the desired mutation. To accomplish this 
step, the recombinant vector with the appropriate mutant cDNA was isolated from DH5α cells. 
Then, 375 ng of each recombinant vector was sent to the Centre for Applied Genomics (TCAG) 
sequencing facility where each mutant cDNA was confirmed to have the required mutation.  
After the nucleotide sequence of each mutant cDNA was confirmed, the recombinant vectors 
were later transformed into chemically competent BL21-Codon Plus- RIPL cells (BL21 CD
+
) via 
heat shock [72]. The transformed cells were grown on a kanamycin (50 μg/mL) selective media 
for 18 h at 37 
o
C. Three positive colonies were selected from each plate and grown in 10 mL LB 
broth that had 25 μg/ml chloramphenicol (cam), 50 μg/ml kanamycin (kan), and 25 μg/ml 
streptomycin (strep), at 37 
o
C, 240 rpm for 16 h. Next, the recombinant vector was isolated from 
BL21 CD
+
 cells and double digested with both NcoI-HF and HindIII-HF restriction enzymes to 
confirm colonies that contained the recombinant vector. Colonies with the vector were stored at 
80 
o
C in glycerol stocks. 
 
3.2.4. Overexpression of Native and Mutant UCP2 in Bl21 CD
+
 Cells 
 The second phase of this project was to express the mutant and wild type UCP2 proteins in 
BL21 CD
+
 cells using the auto-induction method [52]. Firstly, under sterile conditions, 20 mL 
LB broth that contained 25 μg/mL cam, 25 μg/mL strep, and 50 μg/mL kan was inoculated with 
a glycerol stock of either the wild type or mutant UCP2 constructs. The overnight culture was 
grown in a shaking incubator at 37 
o
C, 240 rpm for 18 h. The next day, the overnight culture was 
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used to inoculate an autoclaved ZY media that was prepared with 930 mL water, 10 g of tryptone 
and 5 g of yeast extract in a 2800 mL Fernbach culture flask. The ZY media was prepared for 
auto-induction with the addition of: 1 mL of 1M MgSO4, 20 mL of 50X 5052 [25% glycerol 
(w/v) 2.5% glucose and 10% lactose], 50 mL of 20X NPS [composed of 0.5 M (NH4)2SO4,         
1 M KH2PO4, 1 M Na2HPO4)], as well as, 50 μg/mL kan, 25 μg/mL cam and 25 μg/mL strep. 
Bacteria cells were grown in the auto-induced media with shaking at 22 °C, 250 rpm, for 22 h. 
The cells were collected by centrifugation at 8000xg for 15 min at 4 
o
C (JLA-10.500 rotor, 
Beckman Coulter) and cell pellets were stored at -20 
o
C. 
 
3.2.5. Protein Extraction from Bacteria Cells and Purification with 
Immobilized Metal Affinity Chromatography (IMAC).   
 The mutant and native UCP2 were isolated from bacterial membranes as described 
previously [68]. Briefly, the cell pellets obtained from a 2L cell culture were resuspended in     
20 mL extraction buffer (20mM Tris-HCl pH 8.0, 500mM NaCl), 1 tablet of c0mplete protease 
inhibitor cocktail tablet EDTA-free, 0.5 mg/mL DNase, and 0.2 mg/mL of lysozyme. The 
resuspended cells were incubated on a vertical rotator at 4 
o
C for 30 min and afterwards, the cells 
were lysed at 4 
o
C, 20 kPsi using a Constant Cell Disruption system T2/40/BA/AA (Constant 
Systems).  The lysed cells were centrifuged at 20,000xg for 20 min at 4 
o
C to separate unbroken 
cells and inclusion bodies (pellets) from the membrane and soluble proteins (supernatant). The 
supernatant was ultracentrifuged at 76,000 rpm, 4 
o
C, for 1 h in an Optima™ Max ultracentrifuge 
(Beckman-Coulter) using an MLA80 rotor (Beckman-Coulter). This step separated soluble 
proteins (supernatant) from bacterial membranes (pellet) [68].  
 Using a 20 gauge needle attached to a 3 mL syringe, the bacterial membranes were 
resuspended in binding buffer (20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 1%  LDAO, 20 mM 
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Imidazole and 1 mM THP, pH 8.0). The detergent solubilized membrane was transferred to a       
25 mL Erlenmeyer flask and stirred at 4 
o
C for 2.5 h. After incubation, the solubilized membrane 
was centrifuged at 8000xg for 10 min at 4 
o
C to separate insoluble particles (pellet) from the 
membrane fraction (supernatant) [68]. The membrane fraction was then passed through an 
IMAC column packed with 4 mL Ni-NTA resin that was pre-equilibrated with 40 mL of binding 
buffer. The membrane fraction was passed through the column three times to maximize binding 
of the his-tagged proteins to the column. After that, the IMAC column was washed with 20 mL 
wash buffer (20 mM Tris-HCl pH8.0, 0.5 M NaCl, 1% OG, 30 mM imidazole, and 1 mM THP) 
to remove loosely bound proteins. The proteins tightly bound to the IMAC column were eluted 
from the IMAC with 10 mL elution buffer (20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 1% OG), 
400mM imidazole 1mM THP) and ten 1 mL fractions were collected [68].  
 All 400 mM imidazole eluted fractions where pooled and concentrated using Amicon 
Ultra-15 Centrifugal Filter (Merck Millipore).  The centrifugal filter used had a molecular weight 
(MW) cut off of 10 kDa. The filter was equilibrated with 2 mL of elution buffer by centrifuging 
in a swinging bucket rotor at 4000xg, 4 
o
C for 15 mins. The 10 mL eluted fractions were loaded 
onto the centrifugal filter and centrifuged at 4000xg, 4 
o
C for 11 mins [7]. The samples were 
concentrated to 3 mL (3x concentrated) and buffer exchanged into desalt buffer (20 mM Tris-
HCl pH 8.0, 50 mM NaCl, 1% glycerol and 1% OG), using an Econo-Pac®10DG Desalting 
Prepacked Column (GE Healthcare). The concentration of proteins in the desalt fractions were 
either measured with a Bradford assay or a modified Lowry assay, using bovine serum albumin 
(BSA) as standards [68]. Afterwards, the most concentrated desalted protein fractions were 
stored at -80 
o
C. 
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3.2.6. Sodium Dodecyl Sulfate Polyacrylamide (SDS PAGE) Gel 
Electrophoresis of Purified Proteins  
 SDS-PAGE was used to analyze the purity and identify of purified UCP2 wild type and 
mutant proteins based on molecular size. Approximately 20 ng of desalted UCP2 proteins, in 1x 
SDS sample buffer (10% glycerol, 50 mM Tris-HCl pH 6.8, 1% SDS, and 75 mM DTT) was 
loaded into the wells of the 4% acrylamide stacking SDS-PAGE gel. The gel was run at 105 V 
for 75 min to separate the proteins in 12% resolving SDS-PAGE gel. After which, the gel was 
stained with Coomassie Brilliant Blue for 2 h and destained overnight in 45% methanol and 10% 
acetic acid solution. The protein bands on the destained SDS-PAGE gel were viewed on the 
VersaDoc 4000 Gel Imaging System. 
 
3.2.7. Optimization of the Purification Procedure for Wild Type and Mutant 
UCP2 Proteins   
 SDS-PAGE analyses of the native and mutant proteins identified higher and lower 
molecular proteins that co-purified with the desired proteins. As a result, an imidazole step 
gradient was used to improve the purity of the proteins [73]. The proteins were extracted from 
bacterial membranes using the procedure described in section 3.2.5. However, after the 
resuspended membrane fraction was loaded onto the IMAC column in binding buffer and 
washed with 30 mM imidazole buffer, a 4 mL wash buffer that contained 75 mM imidazole was 
applied to the column. The column was further washed with a 4 mL wash buffer that contained 
100 mM imidazole, while the remaining proteins bound to the IMAC column were eluted with 
10 mL of 400 mM imidazole containing elution buffer. The collected fractions from the wash 
and the elution buffers were analyzed on an SDS-PAGE gel. Although protein purity improved 
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from the previous purification procedure, the amount of proteins in the purest fractions was 
insufficient for biophysical analysis.  
 In order to maximize protein purity and yield, the following imidazole concentrations were 
used to purify wild type and mutant UCP2 proteins: 10 mM imidazole in the binding buffer,     
75 mM imidazole in the wash buffer, and 400 mM imidazole in the elution buffer. The most 
concentrated protein fractions eluted with 400mM imidazole were desalted in 1% OG. This 
modified purification protocol was used to purify all mutant and native UCP2 proteins because 
the SDS-PAGE indicated increased protein purity with sufficient concentrations for further in 
vitro studies. 
 
3.2.8. Western Blot Analysis of Purified Proteins 
 The isolated native and mutant UCP2 proteins were verified with the Western blot 
technique. Firstly, all proteins were loaded onto an SDS-PAGE gel and run under conditions 
described in section 3.2.6. Rather than staining the gel, the proteins separated on the gel were 
transferred onto a nitrocellulose membrane at 15 V for 120 min, using the semi-dry transfer 
method [68]. Next, the nitrocellulose membrane was stained with Amido Black to confirm 
transfer efficiency, followed by blocking the membrane in TBS-T (10 mM Tris-HCl, 150 mM 
NaCl, 0.05% Tween 20, pH 7.5) buffer, containing 5% skim milk, overnight at 4
o
C [68]. The 
nitrocellulose membrane was probed with a primary antibody, rabbit IgG anti-UCP1/2/3    
(1:2000 dilution) for 2h on a horizontal shaker. Afterwards, anti-rabbit IgG peroxidase-
conjugated antibody (1:20,000 dilution) raised in goat was used as the secondary antibody. 
Immunodetection was achieved by luminescence with a Western blot HRP (horse radish 
peroxidase) substrate, and the detected proteins were observed on a Bio-Rad VersaDoc 4000 
Imaging System.  
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3.2.9. Structural Analysis of UCP2 Proteins by CD Spectroscopy. 
The third phase of this project was to analyze the overall secondary structure of the 
purified UCP2 native and mutant proteins with CD spectroscopy. Firstly, the concentration of 
each purified protein in desalt buffer (20 mM Tris-HCl pH 8.0, 50 mM NaCl, 1% glycerol and 
1% OG) were quantified with the modified Lowry assay as described in 4.1.8. Secondly, 300 μL 
of each protein (concentrations between 5 - 8.3 μM) was transferred into a 0.1 cm path length 
quartz cuvette and far-UV CD spectroscopic measurements at 25 
o
C were performed in an Aviv 
215 spectropolarimeter (Aviv Biomedical, Lakewood, NJ). The AVIV CDSD software was used 
to subtract the CD spectra of the blank buffer from that of the protein, to correct for any 
background signal caused by buffer components. This software also converted the CD spectra 
reported in millidegrees to mean molar residue ellipticity (molar ellipticity).  
Furthermore, the CDSSTR (CD secondary structure) deconvolution program website 
estimated the α-helical contents of the proteins from the far-UV CD spectra. This analysis was 
performed on the Dichroweb website and was based on a set of 48 reference proteins [74, 75]. 
 
3.2.10. Reconstitution of UCP2 Proteins into Liposomes 
 As a means to perform ion flux measurements on UCP2 proteins a detergent-mediated 
reconstitution method was used to embed the proteins into liposomes [57, 68]. First, 100 mg/mL 
stock of L-α-lecithin phospholipids was dissolved in 75% chloroform and 25% methanol, and 
stored in a sealed glass vial at - 40 
o
C. Next, 30 mg of the 100 mg/mL lipid stock was transferred 
into a 25 mL round bottom flask (RBF) and a gentle stream of N2 gas was used to evaporate the 
chloroform and dry the lipids as a thin film, along the sides of the flask. The lipids were further 
dried overnight under a vacuum to remove any residual chloroform and methanol. The dried 
lipids were rehydrated with 3 mM SPQ in ultrapure water and with gentle shaking to form 
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MLVs. The RBF was also placed in a bath sonicator and degassed for (10 s), to remove the lipids 
stuck on the sides of the flask. The MLVs were solubilized with the addition of 75 mg C8E4, in a 
detergent to lipid ratio of 2.5:1 by mass. This mixture was incubated on ice for 20 min to 
facilitate the formation of mixed lipid-detergent micelles. 
 For proton transport assays, a protein to lipid weight ratio of ~1:200 was used to maximize 
the amount of proteins incorporated into the lipid vesicles. Moreover, 3 μM stock proteins 
desalted in 1.5x internal buffer (IB) (30 mM TES, 80 mM TEA2SO4, and 1 mM EDTA, pH 7.2, 
1% OG) were added to the mixed micelles. Protein-free liposome (blank liposome) controls were 
made in parallel for all proton transport measurements.  
 Once the proteins were added to the mixed micelles, the composition was flushed with 
argon gas (30 s) to remove any residual oxygen that may oxidize the phospholipids, followed by 
incubation on a stir plate for 1 h 30 min at 4 
o
C. Subsequently, the lipid-detergent-protein 
mixture (1 mL) was incubated in a 3 mL syringe column that contained 1.5 mL SM-2 Biobeads, 
for 2 h at 4 
o
C. Detergent adsorption onto SM-2 Biobeads led to the formation of 
proteoliposomes, as well as the blank liposomes. Once the incubation time elapsed, the 
proteoliposome/blank liposomes were eluted from the columns after centrifuging at 1000 rpm, 
for 1 min at 4 
o
C. Any residual detergent in the proteoliposome/blank liposome samples was 
removed with a second incubation in 1.5 mL SM-2 Biobeads (1 h, 4 
o
C).  The resultant 
proteoliposome was collected by centrifugation as described above. Lastly, 250 μL 
proteoliposome/blank liposome samples were loaded into a gel filtration column composed of       
3 mL coarse grade Sephadex G25-300 gel filtration. The gel filtration columns were pre-
equilibrated with 1x IB and the proteoliposome/blank liposome samples were centrifuged at      
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2000 rpm, 4 
o
C for 2 min (JS 13.1 rotor). Finally, DLS technique was used to measure the size 
and dispersity of the eluted proteoliposomes/blank liposomes.  
 
3.2.11. Size Determination of Liposomes Size by Dynamic Light Scattering 
(DLS) 
Size distribution of the blank liposomes and proteoliposomes were determined with DLS. 
DLS measurements for each sample were obtained after 40 L of sample was loaded onto a 
microplate. The microplate was placed in a DynaPro Plate Reader II (Wyatt Technologies, 
California, U.S.A) and 10 measurements were taken for each sample at 25
 o
C.  
 
3.2.12. Proton Flux Measurement Mediated by UCP2 Proteins 
 The ability of UCP2 wild type and mutant proteins to transport protons across  
reconstituted phospholipid vesicles were determined with an SPQ fluorescence quenching  
 assay (Figure 12) [66]. The assay was performed in a 1 cm pathlength quartz fluorescence 
cuvette and measured with a Cary Eclipse spectrofluorometer (Varian) instrument. The 
fluorescence signal of the SPQ probe was excited at 347 nm and emitted at 442 nm with a 
bandwidth slit of 5 nm. During the measurements, the assay components were constantly stirred 
at 25 
o
C.   
 Proton flux measurements were obtained from an assay that contained 40 μL 
proteoliposome and 1.96 mL external buffer (EB) (80 mM K2SO4, 40 mM K-TES, 1 mM EDTA, 
pH 7.2) in the cuvette. At 30 s, 100 μM palmitic acid (PA) was added to the cuvette, after which 
proton flux was initiated at 1 min with the addition of 1 μM valinomycin. For each scan, the 
kinetics of proton transport was measured for 4 min after adding valinomycin and a minimum of 
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5 scans were conducted for the proteoliposome and blank liposome samples. Proton flux 
measurements were obtained for blank liposomes to measure non-specific proton leakage.   
 Once the proton transport measurements were completed, the data was calibrated for the 
SPQ fluorescence signal. This calibration was achieved with the addition of 40μL 
proteoliposomes to 1.96mL 1x IB in a cuvette [7, 68]. After mixing for 20 s, 2 μL of 1 mM 
Nigericin (a K
+
/H
+
 antiporter) was added, which caused a decrease in the SPQ fluorescence 
signal. At 45 s, and every 15 s afterwards, 2 μL of 2 M KOH was added to the mixture. The 
calibrated fluorescence signal was fitted to the modified Stern-Volmer equation below:  
  
 
   [ 
 ]                 
Where F0 is the initial fluorescence signal before the addition of KOH, F is the fluorescence in 
the presence of KOH, Kq is the Stern-Volmer constant, and [H
+
] is the change of proton 
concentration in the media [7, 66, 68]. The value of  Kq was calculated from the fitted data, and 
subsequently used to convert the measured fluorescence kinetics into proton efflux using 
equation 2: 
[  ]  
     
 
 
 
  
[  ]                
 The internal volume of the proteoliposome was determined with the standard addition 
method to calculate the [SPQ] dye trapped inside the vesicles and comparing it to the original 
[SPQ] used to prepare the proteoliposomes [7, 68]. In brief, 40 μL proteoliposome was added to          
1.96 mL of ultrapure water, and at 20 s, 5 μL of 0.25% (w/v) C8E4 was added to solubilize the 
proteoliposome, upon which an increased fluorescence signal was observed. At 45s, 2.5 μL of 
100 μM SPQ was added every 15 s for a total time of 2min. A plot of fluorescence signal vs 
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[SPQ]added, was used to derive the [SPQ] inside the vesicles. Dividing the [SPQ]proteoliposome by the 
original SPQ [SPQ]0 (i.e. 3mM) yielded the internal volume of the proteoliposome. 
       
[   ]              
[   ] 
              
Furthermore, the plot of H
+
 efflux versus time was used to determine the initial rate of 
proton transport (V) in mM/s.  This rate was corrected for liposome internal volume to yield V’ 
in nmol/s with equation 3 [7, 68].  
                                                       
The rate was corrected for non-specific proton leakage by subtracting the calculated V' in 
nmol/s for blank liposomes and subtracting it from the V' of proteoliposome. This subtracted rate 
was further corrected for total protein content in proteoliposomes, and the final rate of proton 
transport was reported as umol.min
-1
.mg protein
-1 
[7, 68].  
For inhibition assays, 500 μM ATP was added to 40 μL proteoliposome in 1.96 mL EB and 
stirred for 2 min. After that, 100 μM PA and 1 μM valinomycin were added and change in SPQ 
fluorescence signal was measured [7]. All calibrations, as well as the rate of proton transport in 
the presence of ATP were calculated as described in this section.  
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Figure 12: Schematic illustration of the proton transport assay. This assay was set up for the 
internal compartment of proteoliposomes to contain an internal buffer, SPQ fluorescent probe, 
and the protonated form of TES buffer. Outside the proteoliposome was an external buffer that 
had a high concentration of potassium (K
+
).  Despite the difference in buffer composition, the 
ionic strength and pH of both buffers were the same so that osmotic balance was maintained 
before ion flux was initiated with valinomycin (Val). Once valinomycin was added the K
+
 
gradient triggered the influx of K
+
 into proteoliposome. This resulted in the build-up of positive 
charges inside the proteoliposome and allowed fatty acid activated UCP2 protein to transport 
protons out of the proteoliposome. H
+
 efflux by UCP2 caused the deprotonation of TES to TES
-
 
that quenched the SPQ fluorescence signal [66].  
 
3.2.13. Quantification of Total Protein by Modified Lowry Assay 
 Modified Lowry assay was used to measure the concentration of purified UCP2 proteins, 
as well as the final concentration of UCP2 in proteoliposomes. Briefly, purified proteins (20 μL 
and 40 μL), proteoliposomes (130 μL and 150 μL), and BSA standards were diluted to 1 mL in 
ultrapure water. After which, 100 μL of 0.15% (w/v) of sodium deoxycholate (DOC) and  
100 μL trichoroacetic acid (TCA) were added to precipitate the proteins for 10 min at room 
temperature (RT). The protein precipitates were centrifuged at 15000 rpm, 4
o
C for 10 min and 
pellets were thoroughly resuspended in 25 μL of 20% (w/v) SDS. Next, 100 μL of reagent A’ 
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from Bio-Rad RC DC Protein Assay kit (Bio-Rad) was added to the suspension and vortexed. 
The solution was sonicated in a water bath for 5min, cooled at RT for 3 min, and sonicated again 
for 2 min. Afterwards, 800 μL of reagent B was added to sonicated samples before a 30 min 
incubation at 4 
o
C. Lastly, 300 μL of each sample was transferred to a microplate and placed into 
a microplate reader (Varian) for absorbance measurement at 750 nm.  
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CHAPTER 4 – RESULTS 
4.1. Mutation of UCP2 cDNA with Overlap Extension PCR  
 The main objective of this research project was to understand the mechanism of ion 
transport in UCP2. To achieve this objective, lysine residues in the matrix network were changed 
to glutamine so that the role of these residues on the ion transport activity through their salt 
bridge interactions in the matrix network of the protein could be examined.  
In order to accomplish the above goal, the first step was to introduce three single 
mutations and one double mutation denoted by the proteins: K38Q, K141Q, K239Q, and 
K38Q/K239Q into the UCP2 cDNA via overlap extension PCR. The double mutant cDNA was 
generated to study the impact of losing two salt bridge interactions in the matrix network on 
UCP2 ion transport activity. Overlap extension PCR technique used three rounds of PCR to 
create each mutant gene. The double mutant was created by using the K38Q cDNA as the 
template in a separate overlap extension PCR reaction. To verify that the correct length of 
nucleotide base pairs was amplified in each round of PCR, the gel purified products of PCR 
reactions: 1, 2, and 3, were visualized on a 1% agarose gel stained with ethidium bromide. As 
evident in Figures 13A and 13B, the bands next to the 1 kb DNA ladder represents the full-length 
UCP2 cDNA. The size of UCP2 cDNA was ~1.05 kb.  
  Once the mutant genes were produced, the products were cloned into a pET26b(+) vector 
and transformed into DH5α cells. The recombinant constructs were isolated from bacterial cells 
and digested with NcoI-HF and HindIII-HF restriction enzymes to confirm the gene products 
were inserted into the vector. The digested products were loaded onto a 1% agarose gel to 
identify the bands at ~5.36 kb and ~1.05 kb that corresponded to the size of vector and UCP2 
gene respectively (Figure 14A and 14B). Undigested recombinant vector (~6.41 kb) was run 
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along with the digested constructs to ensure the digested DNA bands observed on the agarose gel 
were due to restriction enzyme activity [72].   
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Figure 13: 1% Agarose gel for the overlap extension PCR products used to create the 
UCP2 mutant cDNAs. A) Lane 1 represents the 1kb DNA ladder, lane 2 represents K38Q PCR 
reaction #3 (~1.05 kb), lane 3 represents K38Q PCR reaction #2 (~0.7 kb), and lane 4 represents 
K38Q PCR reaction #3 (~0.35 kb). B) Lane 1 represents K141Q PCR reaction #2 (~0.55 kb), 
lane 2 represents K141Q PCR reaction #1 (~0.5 kb), lane 3 represents K141Q reaction #3 (~1.05 
kb); Lanes 6-8 represent K239Q PCR reactions: #3 (~1.05 kb), #1 (~0.8 kb), and #2 (~0.25 kb) 
respectively. 
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Figure 14: 1% Agarose gel for digested pET26b(+):UCP2-mutant constructs. 
A) Digested and undigested pET26: UCP2-K38Q, K141Q and K239Q cDNA respectively. The 
undigested recombinant vectors were loaded onto the gel as a control: Lane 1 represents DNA 
ladder, lanes 2-7 represent the cut and uncut recombinant vectors for K38Q, K141Q, and K239Q, 
respectively. B) Restriction digest results for pET2b(+):UCP2-K38Q/K239. In both gels, the 
DNA band at ~1.05 kb represents the mutant cDNA while the band at ~5 kb indicates the 
digested vector. The controls had a DNA band above 5 kb which represented the uncut 
recombinant vector.  
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As soon as the DH5α cells were confirmed to contain the UCP2 mutant constructs, the 
recombinant vectors were isolated from the cells and sequenced at the TCAG DNA sequencing 
facility. The sequenced cDNA confirmed the appropriate mutations were incorporated into the 
UCP2 cDNA with overlap extension PCR. The nucleotide sequence of the mutants was aligned 
with wild type UCP2 gene sequence in the NCBI nucleotide blast database [76]. Shown in 
Figures 15 and 16 are the aligned nucleotide sequences for the mutants with the substituted 
codons highlighted in black boxes; AAA:CAA for K38Q mutation, and AAG:CAG for K141Q, 
and AAG:CAG  K239Q.  
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Figure 15: DNA sequencing Results of K38Q, K141Q, and K239Q Primed with T7 
Forward Primer: Sequence alignment of PCR amplified single mutant genes (query) was 
aligned with the UCP2 wild type gene (subject) in the NCBI nucleotide blast database [76]. The 
desired mutations were: AAA:CAA for K38Q mutation, and AAG:CAG for both K141Q and 
K239Q (black boxes). The red box indicates the silent mutation introduced into the wild type 
UCP2 gene to knock out the endogenous NcoI site. This mutation ensured the cDNA remained 
intact when digested with NcoI and HindIII restriction enzymes before ligating into the 
pET26b(+) vector. 
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Figure 16: Results for pET26(+):UCP2-K38Q/K239Q Primed with T7 Forward Primer.  
K38Q/K239Q nucleotide sequence (query) was aligned with the UCP2 wild type gene sequence 
(subject) in the NCBI nucleotide blast database [76]. The desired mutations were: AAA:CAA for 
K38Q mutation AAG:CAG K239Q, as indicated by the black boxes. The red box highlightes the 
knocked out endogenous NcoI restriction site. 
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Once the cDNAs of the pET26b(+):UCP2 mutant constructs were confirmed to have the 
required the mutation, the recombinant vectors were isolated from DH5α and transformed into 
BL21 CD
+
  with heat shock. A restriction double digest of the recombinant vector verified the 
presence of the constructs in BL21 CD
+
 cells due to the bands at ~1.05 kb (UCP2 cDNA) and         
~5 kb (vector) on lanes 2, 4, 6, and 8 (Figure 17). BL21 CD
+
 has two endogenous plasmids one 
of which is a pSC101-based plasmid (~4.7 kb) that encodes a streptomycin resistance gene as 
well as an HindIII cut site [77]. The other plasmid is a pACYC-based plasmid (~3.5 kb) that has 
a chloramphenicol resistant gene and both HindIII and NcoI restriction sites [77]. Therefore, the 
bands at ~1.4 kb and ~1.9 kb correspond to the digested pACYC plasmid. On the other hand, the 
band at ~5 kb may be a combination of the digested pSC101 and pET26b(+) vectors because 
they are relatively similar in size.  
 
 
 
 
 53 
 
 
Figure 17: 1% Agarose gel for restriction enzyme digest of UCP2 mutant constructs 
isolated from BL21-CodonPlus (DE3)-RIPL cells. Lane 1 represents the 1 kb DNA ladder. 
Lanes 2 - 9 represent the digested and undigested recombinant vectors: pET26:UCP2-K38Q, 
pET26b(+):UCP2-K141Q, pET26b(+):UCP2-K239Q, and pET26b(+):UCP2-K38Q/K239Q. All 
digested recombinant vectors have a band at ~1 kb that represents the cDNA while that band at 
~5 kb represents the pET26b(+) vector. The bands at  ~5 kb may also represent the linearized 
pSC101 while the bands at ~1.4 kb and ~1.9 kb represent the digested pACYC plasmid. The 
undigested plasmids (lanes 3, 5, 7, and 9) indicate the endogenous BL21 CD
+
 plasmids at           
~4.7 kb and ~3.5 kb, and also the recombinant pET26b(+) vector at ~5 kb [77]. 
 
4.2. Expression of UCP2 Proteins in Bacterial Membranes and Purification 
with IMAC 
Overexpression of UCP2 mutant and native proteins in BL21 CD
+
 cells was initiated with 
auto-induction as described in 3.2.4. Protein expression was directed towards the bacterial inner 
membrane with a pelB signal peptide encoded by the pET26b(+) vector [68]. The signal peptide 
targets secreted proteins to the periplasmic space via the Sec translocase pathway [49, 50]. 
However, due to hydrophobic interactions, the TM segments of UCP2 proteins are inserted into 
the bacterial membrane during translocation [78]. The bacterial membrane enriched with UCP2 
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proteins was separated from soluble and aggregated (inclusion bodies) proteins after cell lysis 
and ultracentrifugation. In a previous study, SDS-PAGE analysis and NADH oxidase activity 
assays confirmed that the bacterial membranes were enriched with UCP2 proteins [79].  
Once the proteins were extracted from bacterial membranes using detergent 
solubilization, the previously established purification protocol [68, 79] proved insufficient in 
purifying UCP2 from unwanted proteins. The SDS-PAGE for the purified mutant and native 
proteins indicated a band at ~33 kDa represented the UCP2, while other protein bands at:       
~250 kDa, ~150 kDa, ~75 kDa,  ~50 kDa, ~27 kDa, and ~17 kDa were also observed on gel      
(Figure 18). The MW proteins at ~150 kDa and ~75kDa were suspected to be dimer and 
tetrameric forms of the proteins because a gradual dissociation to monomers (~33 kDa) was 
observed when purified UCP2 was titrated with increasing SDS concentrations [79]. On the other 
hand, the lower MW proteins at ~27 kDa and ~17 kDa might be truncated forms of UCP2 
protein. 
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Figure 18: SDS-PAGE of IMAC purified and desalted UCP2 and mutant proteins. The 
purified proteins were resolved on a 12% resolving SDS gel, stained with Coomassie Brilliant 
Blue. The box highlights the ~33 kDa band for UCP2 monomer. Higher and lower molecular 
weight protein bands present on the gel could be multimeric forms of UCP2 or degraded protein 
contaminants respectively. 
 
 To improve protein purity, two wash buffers that contained 75 mM and 100 mM 
imidazole were applied onto the IMAC column after the column was washed with 30 mM 
imidazole wash buffer. After that, the desired proteins were eluted with 400 mM imidazole. 
Although most protein contaminants were removed from the column by the wash buffers, some 
UCP2 proteins also eluted in these fractions which decreased the concentration of UCP2 in     
400 mM fractions (most pure) (Figure 19). Interestingly, UCP2 monomers were the major 
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constituent in the 400 mM imidazole fractions while the multimeric and truncated forms of 
UCP2 were eluted in the wash buffers.  
 
 
 
Figure 19: Purification of UCP2 native protein with step imidazole gradient.                     
The SDS-PAGE shows that most of the higher and lower MW proteins were eluted with 75 mM 
and 100 mM. The fractions eluted with 400 mM imidazole contained the UCP2 monomer with 
the highest purity.   
 
  Although UCP2 monomers were obtained in good purity, the protein concentration in the 
fractions eluted with 400 mM imidazole was insufficient for downstream applications. 
Therefore, to maximize the yield and purity of UCP2 and its mutants, 30 mM imidazole and       
75 mM imidazole were utilized to remove most of the protein contaminants, while 400 mM 
imidazole eluted the dominantly monomeric UCP2 proteins from the IMAC column. Based on 
the SDS-PAGE gel in Figure 20, majority of the higher and lower MW bands were eluted in the 
75 mM imidazole wash buffer with minimal loss of UCP2 monomers in these fractions. The   
400 mM imidazole containing buffer eluted any remaining contaminants and some UCP2 
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monomers in first two fractions while later fractions contained substantial amounts of UCP2 
monomers with a high degree of purity.  
 
 
  
Figure 20: SDS-PAGE for UCP2 wild type purification with 30 mM, 75 mM, and 400 mM 
imidazole concentrations. Only the UCP2 fractions eluted with 75 mM and 400 mM are shown 
on the SDS gel. Most of the higher MW proteins eluted in the 75 mM imidazole wash buffer 
while the UCP2 monomer was obtained in fractions eluted 400 mM imidazole elution buffer. 
The proteins in these fractions had a higher degree of purity and concentration that was sufficient 
for biophysical analysis.  
 
Since the modified protocol purified UCP2 wild type with adequate purity and yield, this 
protocol was also used to purify the single and double mutant proteins. The purified proteins 
were further desalted in a size exclusion column to remove any imidazole that may interfere with 
spectroscopic studies. The desalted proteins were separated on an SDS-PAGE and the UCP2 
monomer at ~33 kDa was identified for all proteins. However, the K38Q/K239Q (double mutant 
(DM)) still had higher molecular weight bands that indicated the presence of dimer and 
tetrameric forms of the protein (Figure 21). In addition, the MW protein ~27 kDa was also 
identified in DM. The band at ~17 kDa present in all proteins was approximately half the size of 
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the UCP2 monomer. Therefore, this protein band was indicated UCP2 degradation by protease 
enzymes that were released from the host cell during cell lysis [80]. 
The identity of each UCP2 protein was verified on a Western blot that was probed with 
an anti-UCP1/2/3 polyclonal antibody (section 3.2.8.). The UCP2 monomer was detected at 
~33kDa while the suspected degraded protein was indicated at ~17 kDa for UCP2-WT and DM 
protein (Figure 22). 
 
 
 
Figure 21: SDS-PAGE results for purified UCP2 wild type (WT) and mutant protein: All 
proteins were expressed in bacterial membranes and purified with IMAC in 1% OG. Purified 
proteins were resolved in a 12% SDS-PAGE gel stained with Coomassie Brilliant Blue. The 
sizes of the Marker are shown in kDa. The band at ~33kDa represents the UCP2 monomer. 
UCP2 dimer at ~75 kDa and tetramer at ~150 kDa were observed for DM. 
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Figure 22: Western blot detection of UCP2 recombinant proteins: The proteins were 
identified with an anti-UCP1/2/3 polyclonal primary antibody raised in rabbit. The Western blot 
was detected with chemiluminescence and the UCP2 protein ~33kDa was observed. 
 
4.3. Far-UV CD Measurements of UCP2 and Mutant Proteins 
 Far-UV CD has previously shown that UCPs have predominantly α-helical conformations 
in detergent micelles and phospholipid vesicles [7, 68, 79, 81]. In this study, the far-UV CD 
spectra determined the conformation of the purified proteins in detergent (1% OG) micelles. 
Blank measurements (buffer containing 1% OG) were subtracted from the proteins CD spectra to 
correct for noise interferences induced by buffer ions and detergent micelles [63]. Subsequently, 
the corrected spectra were converted to mean residue ellipticity which normalized the spectra 
with respect to the cuvette path-length and concentration of proteins used in each  
measurement [63]. The overall conformations of the mutant and native proteins were α-helical 
with local minima at ~208-210nm nm and ~220- 222 nm, as well as a local maximum at 195 nm 
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(not fully observed due to noise at wavelengths below 195nm) (Figure 23). The native UCP2 had 
a negative minima ellipticity at 210 nm and 220 nm. The overlapped CD spectra for K38Q and 
K239Q indicated structural similarities for both proteins. Compared to native UCP2 however, 
these proteins had less negative ellipticities at 210 nm and 220nm. Although the negative minima 
at 220 nm red shifted to 222 nm in K38Q/K239Q (DM), the ellipticities at 210 nm and 220 nm 
for the DM were the least negative of all the proteins. Meanwhile the CD spectra for K141Q 
revealed that the negative ellipticity at 210 nm blue-shifted to 208nm while the shoulder at       
220 nm was relaxed, less negative, and blue shifted toward 219 nm.  
 
 
Figure 23: Far-UV CD spectra for mutant and native UCP2 in detergent micelles. The CD 
spectrum for each protein was the average of 3 scans in mean residue ellipticity K38Q/K239Q 
mutant is indicated as DM in the above spectra. All proteins had an overall α-helical 
conformation in 20mM Tris-HCl pH 8. The protein concentrations used for each measurement 
range from 5 μM – 8 μM. 
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The molar ellipticity ratio (θ208 nm/θ222 nm) estimates the degree of inter-helical packing in 
proteins [68]. A θ208 nm/θ222 nm ratio ≥ 1 indicates a densely packed helical conformation while a 
loosely packed or more relaxed helical conformation is observed at ratios < 1 [68].  All UCP2 
proteins except the DM had a more negative ellipticity at 208 than 222 nm (Table 4). Hence, the 
θ208 nm/θ222 nm (Table 4) identified loosely packed helical conformation for UCP2 and single 
mutant proteins and a more densely packed conformation for the DM.  
The percentage α-helix composition in each protein was analyzed with CDSSTR on the 
Dichroweb website and results of the deconvoluted data are shown in Table 4. Based on the 
deconvoluted data, UCP2-WT has the highest helical content, followed by K38Q, K239Q, 
K38Q/K239Q and K141Q, respectively. 
 
Table 4: Secondary structure composition of UCP2 proteins in detergent micelles. The 
CDSSTR program on the Dichroweb website was used to determine the percentage α-helix 
content from the CD spectra in molar ellipticity [74, 75]. The ratio of θ208/θ222 indicates the 
degree of helical packing in the proteins. 
 
Protein α-Helix 
(%) 
θ222nm θ208nm Ratio of 
θ208/θ222  
UCP2-WT 23 5440 6093 1.12 
K38Q 20 4952 5272 1.06 
K239Q 20 4840 5160 1.06 
K141Q 17 4993 61935 1.24 
K38Q/K239Q 20 4532 4543 0.99 
 
4.4. Liposome Size Determination with DLS 
The purified proteins were reconstituted into phosphotidylcholine vesicles to compare ion 
flux measurements. DLS measured the size and homogeneity of the proteoliposomes to ensure 
LUVs (100 nm – 1 μM diameter) were prepared and vesicles were stable during proton transport 
measurements. Protein-free liposomes (blank liposomes) were made in parallel to 
preoteoliposome to serve as a control for ion transport measurements. In general, the sizes of 
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each proteoliposome were less than the blank; possibly the incorporated protein induced a 
curvature stress on the vesicle that decreased the size of the proteoliposomes (Table 5) [82]. A 
percent polydispersity (%PD) ≤ 20% indicated a relatively monodisperse size distribution while 
a %PD above 20 identified polydispserse size populations [83]. Hence, the size population of 
UCP2-WT, K38Q, and K239Q proteoliposomes were monodisperse while, K141Q, DM and 
protein-free liposomes were ranged from medium to polydisperse size distributions (Table 5). 
 
Table 5: Average diameter (nm) of liposome and proteoliposome used in ion transport 
measurements: The sizes below are the average of three independent preparations. Protein-free 
liposomes (blank liposome) was prepared along with the proteoliposomes. The standard error of 
the mean (SEM) is reported along with the sizes, while the dispersity of the vesicles is 
represented in percent polydispersity (%PD). 
 
Sample Average Diameter ± SEM % PD 
Blank 234 ± 8 31 
UCP2-WT 212 ± 12 16 
K38Q 199 ± 4 18 
K239Q  215 ± 7 20 
K141Q 210 ± 5 31 
K38Q/K239Q 204 ± 13 23 
 
4.5 Proton Transport Measurements for Native and Mutant UCP2  
 The rates of fatty acid-mediated proton transport in mutants were compared to the native 
UCP2.  Proton transport measurements were obtained for reconstituted UCP2 wild type and 
mutant proteins as stated in 3.2.12 [66, 68]. Shown in Figure 24 is the proton efflux (in mM) 
mediated by the proteins (black curve) across phospholipid vesicles after valinomycin was added 
to the assay. Proton efflux across protein-free liposomes (red curve) was also measured to 
account for non-specific leakage induced by the liposome. Overall, each protein had a higher 
proton efflux than the blank liposome. The initial rates of proton transport were calculated within 
the first 25 s after valinomycin addition and corrected for non-specific leakage and total protein 
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content. The calculated proton flux was reported as μmol.min-1.mg protein-1 (Table 6). As 
expected, UCP2-WT had the highest proton flux compared to the mutant proteins. K38Q and 
K239Q had similar transport rates but compared to UCP2-WT, these rates were ~36% and ~34% 
less. The proton flux for K141Q and DM were ~70% and ~71% less than the wild type UCP2. 
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Figure 24: Fatty acid-mediated proton transport by native and mutant UCP2 across 
phospholipid vesicles.  Non-specific proton efflux in protein-free blank liposomes (red) was less 
than the proton efflux in UCP2 proteoliposomes (black). Proton efflux was indirectly measured 
by quenching SPQ fluorescence with the TES anion. The above plot is the average of 3 
independents measurements and the total protein concentration was quantified with modified 
Lowry assay. The protein concentration in proteoliposomes ranged from 0.24 μM – 0.5 μM. 
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Table 6: Corrected proton flux for wild type and mutant UCP2: The reported transport rate 
for each protein are the average rates from three independent measurements ± standard errors of 
the mean (SEM). The final protein content was 0.24 – 0.5µM.  
 
Protein Proton flux in μmol min-1(mg protein)-1± SEM 
UCP2-WT 42.5  ± 2.8 
K38Q 27.5  ±3.6 
K239Q 28.2  ±3.4 
K141Q 13.8  ±0.8 
K38Q/K239Q(DM) 12  ±1.2 
 
4.6. Inhibition of Fatty Acid-Mediated UCP2 Proton Transport  
 Purine nucleotides are known inhibitors of UCP ion transport function as confirmed by 
multiple inhibition assays in past studies [7, 68]. In this study, the impact of ATP on UCP2 (and 
mutants) proton transport activity was measured by incubating each proteoliposome with        
500 μM ATP for 2 min before valinomycin was added to initiate proton transport [7, 68]. The 
proton transport rate was also measured in the absence of ATP for comparison (Figure 25).  
Shown in Figure 25 are the observed proton efflux (mM) as a function of time for UCP2 proteins 
in the presence (red line) and absence (black line) of ATP. The initial rate of proton transport 
(with and without ATP) was corrected for non-specific leakage and protein content in the 
liposome. The percentage decreases in the initial rate of proton transport due to the interaction of 
ATP with the proteins are listed in Table 7. In the presence of ATP, the UCP2-WT proton flux 
decreased by 14% which was indicative of partial nucleotide inhibition [7]. The proton transport 
rates of the mutants were inhibited by ATP to varying extents; K239Q, K141Q and DM proton 
transport rates decreased by less than 7% while K38Q proton transport rate decreased by 38%. 
These preliminary results indicate that the interaction of ATP with UCP2 proteins led to a more 
decreased proton transport rate in K38Q compared to the UCP2-WT and other mutant proteins. 
However, further experiments need to be performed to verify this observation.  
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Figure 25: Inhibition of UCP2 and mutant proton efflux by ATP.  Proton transport assay was 
performed as described in section (4.1.12). Total protein content was quantified with modified 
Lowry assay. The concentration of protein in each proteoliposome ranged from 0.35μM – 
0.55μM. 
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Table 7: Rate of proton flux in the absence and presence of purine nucleotide: Proton 
transport measurements were triggered after incubating the liposomes with 500µM ATP for 
2min. The reported percent decrease rate is the relative change in proton transport rate in the 
absence and presence of inhibitor. 
  
Protein Proton transport rate 
without ATP   
(μmol min-1(mg protein)-1 ) 
Proton transport rate 
with ATP (μmol      
min-1(mg protein)-1 ) 
% Decrease in 
Rate of Proton 
Transport  
UCP2-WT 41 35 14 
K38Q 21.7 13 38 
K239Q 21.7 21 3.2 
K141Q 15.3 14.3 6.5 
K38Q/K239Q(DM) 13.1 12.6 3.8 
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CHAPTER 5 – DISCUSSION, CONCLUSION AND FUTURE 
STUDIES 
5.1. Discussion 
This thesis addressed the impact of lysine amino acids in the matrix network of UCP2 on 
the ion transport mechanism of the protein. These lysine residues are proposed to form a salt 
bridge interaction with oppositely charged amino acids in the matrix network (Figure 6B) [42]. 
Furthermore, the disruption and formation of this salt bridge interaction induced by a bound 
substrate could result in substrate translocation through the protein [42]. Using overlap extension 
PCR and designed primers, mutations were introduced into the UCP2 cDNA to create K38Q, 
K239Q, K239Q, and K38Q/K239Q (DM) in the recombinant protein. Four mutant proteins were 
expressed and purified successfully. As expected, the proton transport activity of the mutants was 
less than the native protein while the effect of these residues on the ATP binding site showed 
different degrees of proton inhibition. These experimental results provide further insight into the 
mechanism of proton uncoupling by UCP2 in the mitochondria. 
 
5.1.1. Expression of UCP2 Proteins in Bacterial Membranes  
Recombinant membrane proteins that are required for biophysical and structural studies 
are typically obtained from bacterial systems in large quantities; however, it is often difficult to 
isolate the protein in their native-folded state [84]. As a result, membrane proteins expressed in 
E.coli  are often extracted from insoluble aggregates (inclusion bodies), followed by the labour 
intensive process of re-folding in detergents that typically yield partially folded proteins [85]. In 
this study, folded recombinant UCP2 proteins were recovered from bacterial membranes by 
using a pelB signal peptide that was encoded on the pET26b(+) vector [49]. The signal peptide 
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targets secreted proteins to the periplasmic space by interacting with a signal recognition particle 
(SRP) and the membrane embedded Sec translocase complex [78]. When the peptide is fused to 
the n-terminus of membrane proteins, the hydrophobic interactions between the TM helices and 
phospholipid bilayer presumably provide an energy barrier that favour the insertion of the 
protein into the inner mitochondrial membrane while the leader sequence is cleaved by a signal 
peptidase in the periplasmic space [78].  
Another challenging aspect in structural studies of membrane proteins in vitro, is the 
isolation and purification of the folded proteins with high yield and purity. In this research 
project, overexpressed UCP2 proteins were extracted from bacterial membranes using detergent 
solubilization [68]. A zwitterionic detergent (LDAO) was used to isolate proteins from the 
phospholipid bilayer by partitioning into the bacterial membrane and dissociating the lipid- 
protein complex in the bilayer [86]. Though LDAO facilitated UCP2 extraction from bacterial 
membranes, the zwitterion may disrupt the native conformation of the protein. Therefore, LDAO 
was exchanged with an uncharged mild detergent (OG) on the IMAC column [68].  
To achieve maximum purity and yield, an imidazole step gradient was used to purify 
UCP2 proteins in its dominantly monomeric form (~33 kDa) (Figure 21). It was previously 
proposed that UCP monomers could associate and form oligomeric states in detergent and lipid 
vesicles [9]. UCP1 and UCP2 were observed to have tetrameric (~150 kDa) conformation on a 
semi-native gel [79]. This observation was also proved when the tetramer dissociated into dimers 
(~75 kDa) and monomers (~33 kDa) in high SDS concentrations [68, 79]. A recent study 
dismissed the notion of an associated stated for UCP1 and claimed the reason for the MW at 
~150 kDa was due to a protein-detergent-lipid complex [87]. The authors also hypothesized that 
cardiolipin was most likely to complex with UCP1 based on isothermal titration calorimetry 
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(ITC) measurements, and the propensity of cardiolipin to interact with IMM proteins. Despite 
this observation, results from both studies indicate that UCPs could form lipid-protein-detergent 
complexes and/or oligomeric complexes.  
Oligomers and lower MW proteins (Figure 18) were observed when UCP2 and its 
mutants were purified with the previously established protocol in our lab [68, 79]. However, 
when a step imidazole gradient was used, majority of the higher MW proteins (dimer and 
tetramer) and protein contaminants eluted in lower imidazole concentrations (30 mM, 75 mM 
and 100 mM) while the UCP2 monomer eluted in the 400 mM imidazole containing elution 
buffer (Figures 19 and 20). The associated forms of UCP2 eluted in 75 mM and 100 mM 
fractions because these conformations may have masked the His-tag which hindered its 
interaction with the Ni-NTA resin [88]. In turn, this enabled the multimeric forms of the protein 
to elute when low imidazole concentration was added to the column. Coincidentally, the 
monomer was also present in these fractions which could also indicate insufficient exposure of 
the His-tag to the Ni-NTA-resin. Despite the loss of UCP2 monomers in fractions eluted with 
most protein contaminants, a sufficient concentration of monomers was obtained in the 400 mM 
imidazole eluted fractions (Figure 21). Compared to the native and mutant proteins, the double 
mutant showed evidence of associated forms as higher MW bands at ~75 kDa and   ~150 kDa 
were identified. In addition to the monomer, a protein band at ~17 kDa was also visible for all 
UCP2 proteins. This band was suspected to be a degraded form of the protein because the protein 
was detected for UCP2 and double mutant proteins on a western blot (Figure 22). In all, UCP2 
monomers were successfully purified with a high degree of purity and yield; but additional 
purification steps such as size exclusion chromatography could be employed to further improve 
the purity of the proteins.  
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5.1.2. Impact of Mutated Lysine Residues on the Structure of UCP2 
Far-UV CD revealed that the secondary structure of the mutant and wild type UCP2 
proteins were comparable. All proteins exhibited an overall α-helical conformation in detergent 
micelles as evident by the local minima at ~208-210 nm and ~220-222 nm in Figure 23. The 
estimated percentage α-helix composition of UCP2-WT and mutant proteins were also similar as 
shown in Table 4. UCP2-WT was estimated to be 23% helical which is less than the 63% α-helix 
composition observed in past studies for UCP2 in detergent [79]. Several strategies can be used 
to increase the alpha helical composition of membrane proteins, such as purifying the proteins in 
detergents that stabilize the α-helices and also reconstituting into phospholipid vesicles which 
was shown in past experiments to induce helical conformations in UCPs [68].  
In this study, the local minimum at 208 was more negative than 222 nm and consequently 
the θ208/θ222 ratio was above 1 for UCP2-WT and single mutants. Experimental results from a 
previous study indicated that UCP1, 2, 4, and 5 had a more negative ellipticity at 208 nm 
compared to 222 nm as well as a molar ellipticity ratio  ≥ 1 when increasing SDS concentrations 
were added to the proteins [68, 79]. It was suggested that the elliptical shifts indicated a change 
in protein conformation from an oligomeric complex to a monomer and hence, the molar 
ellipticity ratio (≥ 1) was indicative of a loosely packed alpha helix [68, 69]. Therefore, the more 
negative ellipticity at 208 nm compared to 222 nm indicated that UCP2-WT and single mutants 
were mostly monomers as shown on the SDS-PAGE. While the similar negative ellipticties at 
208 nm and 222 nm observed for DM represented a mixture of monomers and oligomers as 
observed on the SDS-PAGE (Figure 23).  
The θ208/θ222 ratio differed for each protein as stated in Table 4. The UCP2-WT had a 
loose helical packing due to the θ208/θ222 ratio above 1. Though K38Q and K239Q had similar 
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ratios and signified similar relaxed helical packing conformations, these ratios were 5% less than 
UCP2-WT which indicated a less relaxed helical packing for both mutants. Also, the DM 
exhibited a densely packed helix due to the θ208/θ222 ratio below 1, while K141Q ratio identified 
the helical packing of this protein as 10% more relaxed than UCP2-WT (Figure 26). Overall, 
these results imply that the mutations could have induced a conformational change in the micro-
environment around the glutamine residue due to the loss of the salt bridge interactions and as a 
result altered the helical packing conformation of UCP2.  
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Figure 26: Comparative conformational changes in helical packing of UCP2 and mutants. 
The above image illustrates the helical packing conformations of UCP2 native and mutant 
proteins as determined by the shifts in negative ellipticity and the molar ellipticity ratio 
(θ208/θ222). The size of the triangles represent the degree of helical packing for the proteins, 
where a small triangle indicates densely packed helices and a large triangle represents a 
loose/relaxed helical packing compared to the native UCP2. The green, purple and orange circles 
represents K38 (TM1), K141 (TM3), and K239 (TM5) respectively while the navy blue circles 
represent glutamine (Q). UCP2-WT had a relaxed alpha helical packing conformation (A). K38Q 
(B) and K239Q (C) had similar loose helix packing but the conformations were slightly less 
relaxed than the native protein. The helix packing conformation of K141Q was more relaxed 
(expanded/larger triangle) (D) while the DM was more densely packed (small triangle) (E) 
compared to the native protein. 
 
5.1.3. Reconstitution of UCP2 into Membrane Vesicles 
 Proton transport rates for selective mutants and native UCP2 proteins were successfully 
measured in proteoliposomes after reconstitution. Proteins were embedded into L-α-lecithin 
liposomes using detergent-mediated reconstitution [57]. The sizes of protein-free liposomes were 
larger than proteoliposomes and one possible reason is that proteins may have induced curvature 
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stress on the membrane of phospholipid vesicles [82]. This curvature stress could be due to the 
insertion of protein hydrophobic helices into the membrane bilayer which created a wedge that 
distorted the structure of the phospholipid membrane. In turn, this distortion may be 
compensated for by allowing the phospholipid head groups around the proteins to become tightly 
packed or released from the bilayer, which could lead to decreased liposome size [82].  
 Monodisperse size distribution of liposomes is preferred for ion transport experiments to 
ensure reliability and reproducibility of experimental results. In this study, monodisperse size   
distributions (≤ 20% PD) were obtained for the proteoliposomes of UCP2-WT, K38Q, and 
K239Q, while a polydisperse distribution of liposome sizes (≥ 20 %PD) were observed for 
K141Q and some of the protein-free liposomes (Table 5). A polydisperse size distribution may 
form due to several factors such as: type of phospholipids used, length of incubation with 
polysterene beads, and temperature [57]. In this particular experiment, the suspected source of 
polydisperse populations was during the removal of external SPQ with sephadex. After the 
second Biobead incubation, relatively monodisperse liposomes were produced. On the other 
hand, polydisperse liposomes were later observed after passing the formed vesicles through a 
sephadex gel filtration column. This could be due to the interaction between the phospholipids 
and the gel surface which led to lipid retention and increased the size distribution of  
liposomes [89]. Therefore, decreasing the amount of sephadex may eliminate this problem in 
future studies. In all, each UCP2 protein was successfully reconstituted into lipid vesicles and 
exhibited proton transport and ATP binding activity as discussed in the following sections.  
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5.1.4. Interpretation of Proton Transport Activity in UCP2  
 Conserved amino acid residues in protein families or homologues often imply an 
evolutionary significance for the residues in the structure and or function of these proteins [90]. 
The conserved lysine residues in the matrix network of UCP2 are suggested to participate in a 
salt bridge interaction with oppositely charged aspartate residues to enable the transport of 
substrates (ions) through the protein [42, 43]. Therefore, it was hypothesized that mutating the 
lysine residues to glutamine would destabilize the salt bridge network due to the loss of the 
positive charge on the lysine residue.  
Despite the structural similarity between the UCP2 and mutant proteins, the proton 
transport and nucleotide binding properties differed for each protein as was expected. The proton 
transport activity of UCP2 was higher than the mutants (Table 7). Interestingly, the proton 
transport rate of UCP2 was higher than previously observed for UCP2 isolated from bacterial 
membranes [79]. This high transport rate could be partly due to the decreased helical packing for 
UCP2 monomer purified in this study. In a previous study, higher transport rates were observed 
for UCP1, 2, and 5 after reconstituting into vesicles containing cardiolipin. Similarly, the CD 
spectra and molar elliptic ratios identified a less dense helical packing conformation for the 
proteins and it was suggested that cardiolipin might affect the degree of helical packing that may 
in part, increase proton conductance in UCPs [7, 68, 79]. Based on this observation, the 
monomeric form of UCP2 isolated in this study may have maintained its loosely packed helical 
conformation in liposomes which enabled higher proton transport rates for the protein. To 
confirm this hypothesis, UCP2 conformation in phospholipid vesicles must be measured with 
far-UV CD.  
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In the presence of 500 µM ATP, the proton transport rate of UCP2-WT decreased by 14% 
compared to the uninhibited proton flux. This percent decrease in proton transport rate was less 
than the inhibition of proton flux previously shown for UCP2 [7]. Therefore, inhibition 
experiments for all UCP2 proteins needs to be repeated and reassessed to confirm the observed 
rates are not due to artifacts in reconstituted vesicles.  A higher degree of inhibition can be 
achieved by trapping ATP inside the proteoliposome and adding ATP externally to the assay [7]. 
In addition, by comparing the inhibition of proton transport by ATP on both sides of the 
membrane with the inhibition by external ATP addition, the orientation of the proteins can also 
be determined [7].  
 Unlike the wild type, K38Q and K239Q had similar transport rates that were ~35% less 
than the wildtype. Coincidentally, both proteins had relatively identical conformations but the 
helices were more densely packed in comparison to the native protein. Mutating both amino acid 
residues (DM) induced a more dense helix packing and a transport rate that was 71% less than 
the native protein. UCPs with a dense helical packing has been shown to have decreased 
transport rates compared to its relaxed conformation when reconstituted into cardiolipin 
containing vesicles [7]. The differences in helical packing and proton transport rate for these 
proteins imply that a change in the microenvironment of the glutamine residues may have 
affected UCP2’s ability to induce a helical packing conformation that may have partly influenced 
UCP2 proton transport activity. Therefore, K38 and K239  amino acids may affect the proton 
transport and possible helical packing of UCP2 by participating in the matrix salt bridge 
network.  
Despite the similarities in structure and proton transport activity of K38Q and K239Q, 
both proteins had distinct degrees of proton transport inhibition by ATP (Table 7). The proton 
 77 
 
transport rates of K239Q and DM decreased by < 4% while K38Q proton flux decreased by 38% 
in presence of ATP.  Due to the close proximity of the ATP binding site and matrix network, these 
results imply that K38Q, K239Q and DM may have altered the microenvironment of the arginine 
residues that bind ATP in the protein cavity (Figure 7). In the case of K38Q, this change may 
have stabilized the ATP bound state more effectively than K239Q and DM proteins.  
K141Q had the most relaxed helical conformation and a proton flux that was ~70% less 
than the wild type but similar to the DM. Therefore, K141Q seems to have an effect on proton 
transport rate that was similar to the loss of two lysine residues (K38 and K239) in the matrix salt 
bridge network. The role of K141 in FA-mediated transport activity was also detected in a 
mutagenic study conducted by Berardi and Chou [91] where the mutation of K141 to threonine 
decreased the FA-mediated proton transport of UCP2 by more than 20%. It was also proposed 
that K141could stabilize the carboxylate anion of the fatty acid when bound to UCP2 [91]. In 
spite of this new observation, the rate of proton transport for K141Q only decreased by ~7% in 
the presence of ATP. This implies K141Q mutation may have affected the local environment of 
the nucleotide binding arginine residues due to the absence of the salt bridge interaction 
involving K141. In all, the results obtained in this thesis project indicate that changing lysine to 
glutamine in the matrix network affected the degree of helical packing and altered the proton 
transport property of UCP2 in the presence and absence of purine nucleotide. These observed 
changes in structure and ion transport activity could be due to the loss of salt bridge interactions 
in the matrix network proposed to be involved in the ion transport mechanism of UCP2.   
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5.2. Conclusion and Future Studies 
Despite the discovery of UCP homologues between 1970 and early 2000’s, the 
mechanism of ion transport in these proteins remains poorly understood. To provide an insight 
into the mechanism of ion transport in UCP2, the positively charged lysine residues in its matrix 
salt bridge network were investigated for their effect on proton transport and nucleotide binding 
activity of the protein. As expected, mutating the K38, K141, and K239 to glutamine induced a 
local conformational change in the helical packing and decreased transport rates compared to 
UCP2-WT. Similarly, the K38Q/K239Q (DM) had a densely packed helical conformation and 
lower transport rate compared to the wild type. Of these mutations K141Q and DM had the most 
influence (decrease) on the rate of proton transport in the native protein. Inhibition studies 
indicated that proton transport rates of the mutants and wild type proteins were inhibited to 
varying extents. The proton transport rate of K38Q was the most inhibited by ATP, followed by 
UCP2-WT, K141Q, K239Q, and DM. These results suggest that the change in the 
microenvironment of each lysine residue can play a role in the conformational change of the 
native protein and the affinity for the inhibitor. However, additional experiments must be 
performed to confirm the observed proton transport rates in the presence of ATP. Overall, these 
lysines form salt bridges with oppositely charged aspartate residues in the matrix network of 
UCP2 and possibly induce local conformational changes in the protein that impact proton 
transport and nucleotide inhibition of UCP2. Further studies could be performed to confirm the 
proposed mechanism. These studies include far-UV CD measurements of the mutants and native 
protein in reconstituted vesicles, as well as using far and near-UV CD to measure the effect of 
ATP binding on the structure of UCP2 and its mutants. Previous experiments have shown that 
cardiolipin can affect the structure and ion transport activity of UCPs. Hence, the impact of 
 79 
 
cardiolipin on the proton and anion transport activity and structure of UCP2 mutants in 
reconstituted liposome can be measured in future studies. Finally, the charged pair interactions 
can be mutated (e.g. K38Q/D236N, K141Q/D35N and K239Q/D138N) to study the effect on ion 
transport activity of UCP2. In conclusion, this study provided experimental evidence that 
indicates the importance of lysine residues in the salt bridge matrix network on the uncoupling 
mechanism of proton transport mediated by UCP2. In turn, understanding the mechanism of 
proton transport in UCP2 could improve the development of therapeutic agents for deleterious 
physiological conditions associated with UCP2 activity such as type II diabetes and cancer [9]. 
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APPENDICES 
Appendix 1 - Sequence Alignment of UCP Homologues and ADP/ATP carrier 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
sp|P02722|ADT1_BOVIN      --------------------------------MSDQALSFLKDFLAGGVAAAISKTAVAP 28 
sp|P25874|UCP1_HUMAN      ----------------------MGG-----LTASDVHPTLGVQLFSAGIAACLADVITFP 33 
sp|P55851|UCP2_HUMAN      ----------------------MVG-----FKATDVPPTATVKFLGAGTAACIADLITFP 33 
sp|P55916|UCP3_HUMAN      ----------------------MVG-----LKPSDVPPTMAVKFLGAGTAACFADLVTFP 33 
sp|O95847|UCP4_HUMAN      --------------------MSVP-EEEERLLPLTQRWPRASKFLLSGCAATVAELATFP 39 
sp|O95258|UCP5_HUMAN      MGIFPGIILIFLRVKFATAAVIVSGHQKSTTVSHEMSGLNWKPFVYGGLASIVAEFGTFP 60 
                                                                     :. .* *: .:.  . * 
 
sp|P02722|ADT1_BOVIN      IERVKLLLQVQHASKQ------ISAEKQYKGIIDCVVRIPKEQGFLSFWRGNLANVIRYF 82 
sp|P25874|UCP1_HUMAN      LDTAKVRLQVQGECP-------TSSVIRYKGVLGTITAVVKTEGRMKLYSGLPAGLQRQI 86 
sp|P55851|UCP2_HUMAN      LDTAKVRLQIQGESQGPVR---ATASAQYRGVMGTILTMVRTEGPRSLYNGLVAGLQRQM 90 
sp|P55916|UCP3_HUMAN      LDTAKVRLQIQGENQAV-Q---TARLVQYRGVLGTILTMVRTEGPCSPYNGLVAGLQRQM 89 
sp|O95847|UCP4_HUMAN      LDLTKTRLQMQGEAALARLGDGARESAPYRGMVRTALGIIEEEGFLKLWQGVTPAIYRHV 99 
sp|O95258|UCP5_HUMAN      VDLTKTRLQVQGQSIDARF-----KEIKYRGMFHALFRICKEEGVLALYSGIAPALLRQA 115 
                          :: .*  **:*                 *:*:.     : . :*    : *    : *   
 
sp|P02722|ADT1_BOVIN      PTQALNFAFKDKYKQIFLGGVDR-HKQFWRYFAGNLASGGAAGATSLCFVYPLDFARTRL 141 
sp|P25874|UCP1_HUMAN      SSASLRIGLYDTVQEFLTAGKETA-PSLGSKILA----GLTTGGVAVFIGQPTEVVKVRL 141 
sp|P55851|UCP2_HUMAN      SFASVRIGLYDSVKQFYT-KGSEH-ASIGSRLLA----GSTTGALAVAVAQPTDVVKVRF 144 
sp|P55916|UCP3_HUMAN      SFASIRIGLYDSVKQVYTPKGADN-SSLTTRILA----GCTTGAMAVTCAQPTDVVKVRF 144 
sp|O95847|UCP4_HUMAN      VYSGGRMVTYEHLREVVFGKSEDEHYPLWKSVIG----GMMAGVIGQFLANPTDLVKVQM 155 
sp|O95258|UCP5_HUMAN      SYGTIKIGIYQSLKRLFVERLEDET--LLINMIC----GVVSGVISSTIANPTDVLKIRM 169 
                               .:   :  :..           :   .      *  :*  .     * :. : :: 
 
sp|P02722|ADT1_BOVIN      AADVGKGA--AQREFTGLGNCITKIFKSDGLRGLYQGFNVSVQGIIIYRAAYFGVYDTAK 199 
sp|P25874|UCP1_HUMAN      QAQSHLHGI--KPRYTGTYNAYRIIATTEGLTGLWKGTTPNLMRSVIINCTELVTYDLMK 199 
sp|P55851|UCP2_HUMAN      QAQARAGG---GRRYQSTVNAYKTIAREEGFRGLWKGTSPNVARNAIVNCAELVTYDLIK 201 
sp|P55916|UCP3_HUMAN      QASIHLGPSRSDRKYSGTMDAYRTIAREEGVRGLWKGTLPNIMRNAIVNCAEVVTYDILK 204 
sp|O95847|UCP4_HUMAN      QMEGKRKLEGKPLRFRGVHHAFAKILAEGGIRGLWAGWVPNIQRAALVNMGDLTTYDTVK 215 
sp|O95258|UCP5_HUMAN      QAQGSLFQ-------GSMIGSFIDIYQQEGTRGLWRGVVPTAQRAAIVVGVELPVYDITK 222 
                            .             .   .   *    *  **: *   .     :     . .**  * 
 
sp|P02722|ADT1_BOVIN      GMLPDPK--NVHIIVSWMIAQTVTAVAGLVSYPFDTVRRRMMMQS-GRKGADIMYTGTVD 256 
sp|P25874|UCP1_HUMAN      EAFVKNNILADDVPCHLVSALIAGFCATAMSSPVDVVKTRFINSPP------GQYKSVPN 253 
sp|P55851|UCP2_HUMAN      DALLKANLMTDDLPCHFTSAFGAGFCTTVIASPVDVVKTRYMNSAL------GQYSSAGH 255 
sp|P55916|UCP3_HUMAN      EKLLDYHLLTDNFPCHFVSAFGAGFCATVVASPVDVVKTRYMNSPP------GQYFSPLD 258 
sp|O95847|UCP4_HUMAN      HYLVLNTPLEDNIMTHGLSSLCSGLVASILGTPADVIKSRIMNQPRDKQGRGLLYKSSTD 275 
sp|O95258|UCP5_HUMAN      KHLILSGMMGDTILTHFVSSFTCGLAGALASNPVDVVRTRMMNQR-AIVGHVDLYKGTVD 281 
                            :         .      :          . * *.:: * : .          * .  . 
 
sp|P02722|ADT1_BOVIN      CWRKIAKDEGPKAFFKGAWSNVLRGMGG-AFVLVLYDEIKKFV----------- 298 
sp|P25874|UCP1_HUMAN      CAMKVFTNEGPTAFFKGLVPSFLRLGSWNVIMFVCFEQLKRELSKSRQTMDCAT 307 
sp|P55851|UCP2_HUMAN      CALTMLQKEGPRAFYKGFMPSFLRLGSWNVVMFVTYEQLKRALMAACTSREAPF 309 
sp|P55916|UCP3_HUMAN      CMIKMVAQEGPTAFYKGFTPSFLRLGSWNVVMFVTYEQLKRALMKVQMLRESPF 312 
sp|O95847|UCP4_HUMAN      CLIQAVQGEGFMSLYKGFLPSWLRMTPWSMVFWLTYEKIREMSGVSPF------ 323 
sp|O95258|UCP5_HUMAN      GILKMWKHEGFFALYKGFWPNWLRLGPWNIIFFITYEQLKRLQI---------- 325 
                                  **  :::**   . **      .. : :::::.  
 
Figure A1: Sequence alignment of bovine ATP/ADP 1 carrier protein (ADT1) and human 
uncoupling protein 1, 2, 3, 4, and 5 in Clustal O 2.1 [95]. The alignment shows the charged 
amino acid residues amino acids residues of the matrix salt-bridge motifs that are conserved 
amongst ADT1 and the UCP homologues (highlighted in yellow). The arginine residues (R88, 
R185, and R279) that bind purine nucleotides in UCP2 are highlighted in green. The accession 
numbers from protein data bank are written beside each protein. 
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Appendix 2 - T7 Terminator Sequenced cDNA for K38Q, K141Q, and K239Q 
 
 
Figure A2-1: Sequence alignment of PCR T7 Primed K38Q (query) and hUCP2wt cDNA             
(subject) in NCBI nucleotide blast database. [96] 
 90 
 
 
Figure A2-2: Sequence alignment of T7 terminator Primed K141 (query) and hUCP2wt cDNA             
(subject) in NCBI nucleotide blast database [76]  
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Figure A2-3: Sequence alignment of PCR T7 Terminator Primed K239Q (query) and hUCP2wt 
cDNA (subject) in NCBI nucleotide blast database [76].  
